Cover Page
Cover Page - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2021 | Mar. 23, 2022 | Jun. 30, 2021 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Period End Date | Dec. 31, 2021 | ||
Current Fiscal Year End Date | --12-31 | ||
Document Transition Report | false | ||
Entity File Number | 001-39011 | ||
Entity Registrant Name | EXICURE, INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 81-5333008 | ||
Entity Address, Address Line One | 2430 N. Halsted St. | ||
Entity Address, City or Town | Chicago | ||
Entity Address, State or Province | IL | ||
Entity Address, Postal Zip Code | 60614 | ||
City Area Code | 847 | ||
Local Phone Number | 673-1700 | ||
Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
Trading Symbol | XCUR | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | true | ||
ICFR Auditor Attestation Flag | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 114.9 | ||
Entity Common Stock, Shares Outstanding (In shares) | 122,792,877 | ||
Documents Incorporated by Reference | Portions of the registrant’s definitive Proxy Statement for the 2022 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference in Part III, Items 10-14 of this Form 10-K. | ||
Entity Central Index Key | 0001698530 | ||
Document Fiscal Year Focus | 2021 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Audit Information
Audit Information | 12 Months Ended |
Dec. 31, 2021 | |
Audit Information [Abstract] | |
Auditor Name | KPMG LLP |
Auditor Location | Chicago, IL |
Auditor Firm ID | 185 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 34,644 | $ 33,262 |
Short-term investments | 4,497 | 48,818 |
Accounts receivable | 0 | 11 |
Prepaid expenses and other assets | 4,525 | 4,231 |
Total current assets | 43,666 | 86,322 |
Property and equipment, net | 3,927 | 4,123 |
Right-of-use asset | 7,950 | 8,606 |
Other noncurrent assets | 9,325 | 1,393 |
Total assets | 64,868 | 100,444 |
Current liabilities: | ||
Current portion of long-term debt | 6,873 | 0 |
Accounts payable | 3,413 | 1,866 |
Accrued expenses and other current liabilities | 6,464 | 3,525 |
Deferred revenue, current | 17,317 | 8,343 |
Total current liabilities | 34,067 | 13,734 |
Long-term debt, net | 0 | 16,589 |
Deferred revenue, noncurrent | 11,509 | 0 |
Lease liability, noncurrent | 7,404 | 7,959 |
Other noncurrent liabilities | 656 | 656 |
Total liabilities | 53,636 | 38,938 |
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, December 31, 2021 and December 31, 2020 | 0 | 0 |
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 108,783,144 issued and outstanding, December 31, 2021; 87,651,352 issued and outstanding, December 31, 2020 | 11 | 9 |
Additional paid-in capital | 181,290 | 167,379 |
Accumulated other comprehensive (loss) income | (2) | 83 |
Accumulated deficit | (170,067) | (105,965) |
Total stockholders' equity | 11,232 | 61,506 |
Total liabilities and stockholders’ equity | $ 64,868 | $ 100,444 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 108,783,144 | 87,651,352 |
Common stock, shares outstanding (in shares) | 108,783,144 | 87,651,352 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | ||
Collaboration revenue | $ (483,000) | $ 16,613,000 |
Total revenue | (483,000) | 16,613,000 |
Operating expenses: | ||
Research and development expense | 48,979,000 | 32,094,000 |
General and administrative expense | 13,087,000 | 9,955,000 |
Total operating expenses | 62,066,000 | 42,049,000 |
Operating loss | (62,549,000) | (25,436,000) |
Other (expense) income, net: | ||
Dividend income | 8,000 | 47,000 |
Interest income | 141,000 | 972,000 |
Interest expense | (1,691,000) | (573,000) |
Other (expense) income, net | (11,000) | 322,000 |
Total other (expense) income, net | (1,553,000) | 768,000 |
Net loss before provision for income taxes | (64,102,000) | (24,668,000) |
Provision for income taxes | 0 | 0 |
Net loss | $ (64,102,000) | $ (24,668,000) |
Basic loss per common share (in USD per share) | $ (0.72) | $ (0.28) |
Diluted loss per common share (in USD per share) | $ (0.72) | $ (0.28) |
Weighted-average basic common shares outstanding (in shares) | 88,617,332 | 87,203,588 |
Weighted-average diluted common shares outstanding (in shares) | 88,617,332 | 87,203,588 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (64,102) | $ (24,668) |
Unrealized (losses) gains on available for sale securities, net of tax | (85) | 110 |
Other comprehensive (loss) income | (85) | 110 |
Comprehensive loss | $ (64,187) | $ (24,558) |
CONSOLIDATED STATEMENT OF CHANG
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in- Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) |
Beginning balance (in shares) at Dec. 31, 2019 | 86,069,263 | ||||
Stockholders equity, beginning balance at Dec. 31, 2019 | $ 80,747 | $ 9 | $ 162,062 | $ (81,297) | $ (27) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of options (in shares) | 500,905 | ||||
Exercise of options | 367 | 367 | |||
Equity-based compensation | 2,184 | 2,184 | |||
Issuance of common stock and warrants, net (in shares) | 1,081,184 | ||||
Issuance of common stock and warrants | 2,766 | $ 0 | 2,766 | ||
Other comprehensive income, net | 110 | 110 | |||
Net loss | (24,668) | (24,668) | |||
Ending balance (in shares) at Dec. 31, 2020 | 87,651,352 | ||||
Stockholders equity, ending balance at Dec. 31, 2020 | $ 61,506 | $ 9 | 167,379 | (105,965) | 83 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of options (in shares) | 342,246 | 342,246 | |||
Exercise of options | $ 546 | 546 | |||
Equity-based compensation | 2,939 | 2,939 | |||
Vesting of restricted stock units and related repurchases (in shares) | 24,257 | ||||
Vesting of restricted stock units and related repurchases | (14) | (14) | |||
Issuance of common stock-ESPP (in shares) | 189,221 | ||||
Issuance of common stock-ESPP | 209 | 209 | |||
Issuance of common stock and warrants, net (in shares) | 20,576,068 | ||||
Issuance of common stock and warrants | 10,233 | $ 2 | 10,231 | ||
Other comprehensive income, net | (85) | (85) | |||
Net loss | (64,102) | (64,102) | |||
Ending balance (in shares) at Dec. 31, 2021 | 108,783,144 | ||||
Stockholders equity, ending balance at Dec. 31, 2021 | $ 11,232 | $ 11 | $ 181,290 | $ (170,067) | $ (2) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (64,102) | $ (24,668) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation and amortization | 1,123 | 766 |
Amortization of right-of-use asset | 656 | 681 |
Equity-based compensation | 2,939 | 2,184 |
Amortization of long-term debt issuance costs and fees | 284 | 111 |
Amortization of investments | 184 | 319 |
Other | 7 | 68 |
Change in fair value of warrant liabilities | (15) | (399) |
Changes in operating assets and liabilities: | ||
Accounts receivable | 11 | 24 |
Prepaid expenses and other current assets | (295) | (3,000) |
Other noncurrent assets | 68 | (161) |
Accounts payable | 1,582 | 364 |
Accrued expenses | 2,811 | 1,174 |
Deferred revenue | 20,483 | (16,486) |
Other liabilities | (555) | (247) |
Net cash used in operating activities | (34,819) | (39,270) |
Cash flows from investing activities: | ||
Purchase of available for sale securities | (6,497) | (56,640) |
Proceeds from sale or maturity of available for sale securities | 50,550 | 69,953 |
Capital expenditures | (968) | (3,171) |
Net cash provided by investing activities | 43,085 | 10,142 |
Cash flows from financing activities: | ||
Proceeds from common stock offering | 11,486 | 2,973 |
Payment of common stock financing costs | (1,111) | (207) |
Proceeds from long-term borrowing | 0 | 17,500 |
Payment of long-term debt fees and issuance costs | 0 | (504) |
Repayment of long-term debt | (10,000) | (4,999) |
Proceeds from issuance of employee stock purchase plan | 209 | 0 |
Proceeds from exercise of common stock options | 546 | 367 |
Payments for minimum statutory tax withholding related to net share settlement of equity awards | (14) | 0 |
Net cash provided by financing activities | 1,116 | 15,130 |
Net increase (decrease) in cash, cash equivalents, and restricted cash | 9,382 | (13,998) |
Cash, cash equivalents, and restricted cash - beginning of period | 34,462 | 48,460 |
Cash, cash equivalents, and restricted cash - end of period | 43,844 | 34,462 |
Supplemental disclosure of cash flow information | ||
Right-of-use asset acquired through operating leases | 0 | 8,147 |
Capital expenditures (accounts payable and accrued expenses) | 9 | 43 |
Debt fees (accrued expense and other noncurrent liabilities) | 0 | 656 |
Common stock issuance costs (accounts payable and accrued expenses) | 142 | 0 |
Cash and cash equivalents | 34,644 | 33,262 |
Restricted cash included in other noncurrent assets | 9,200 | 1,200 |
Total cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows | $ 43,844 | $ 34,462 |
Description of Business and Bas
Description of Business and Basis of Presentation | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Description of Business and Basis of Presentation | Description of Business and Basis of Presentation Description of Business Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. The Company’s therapeutic discovery and development efforts are supported by its proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. The Company believes the design of SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. The Company’s platform for therapeutic nucleic acids has demonstrated potential high potency, broad uptake, and prolonged efficacy in both in vitro and in vivo neurological models. The basis of the Company’s discovery approach harnesses our expertise in oligonucleotide chemistry for use against validated targets where we can screen thousands of oligonucleotides efficiently and identify top candidates in the appropriate cell and live animal models. The Company is conducting preclinical studies for a non-opioid analgesic directed against SCN9A (Nav1.7); undisclosed targets in Huntington’s disease and Angelman syndrome as part of our collaboration with Ipsen Biopharm Limited, or Ipsen; and undisclosed targets in hair loss disorders as part of our collaboration with AbbVie Inc., or AbbVie. Throughout these consolidated financial statements, the terms the “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc. Basis of Presentation The accompanying consolidated financial statements as of December 31, 2021 and 2020, and for the years then ended, have been presented in conformity with generally accepted accounting principles in the United States (“GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation. Significant Risks and Uncertainties As discussed in Note 3, Collaborative Research and License Agreements , revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, Collaborative Research and License Agreements ) for the year ended December 31, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of recorded in connection with a change in estimate that occurred during the third quarter of 2021. The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement. These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the year ended December 31, 2021 as compared to the amount of revenue recognized at December 31, 2020, which led to a full year revenue reversal of $(2,792) in the current year. Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the near-term which may result in additional adjustments (reductions of revenue) in future periods. As discussed in Note 2, Significant Accounting Policies — Revenue Recognition , determining the estimate of total project hours used to recognize revenue for the Company’s collaboration agreements requires significant judgment and any changes to those estimates may have a significant impact on the amount and timing of revenue recognition for the Ipsen Collaboration Agreement or the AbbVie Collaboration Agreement (each, as defined in Note 3, Collaborative Research and License Agreements ) in future periods. COVID-19 Risks and Uncertainties In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company continues to monitor closely the developments and continue to take active measures to protect the health of its employees and their families, and its communities. Its on-site activities continue with protocols for safely accessing and working within its facilities. While the Company continues to conduct research and development activities, the COVID-19 pandemic has impacted, and may continue to impact, certain of its early-stage discovery efforts. The Company is working closely with its third-party manufacturers and other partners to manage its supply chain activities and mitigate potential disruptions as a result of the COVID-19 pandemic. The Company has observed minor delays in receipt of key chemicals, reagents and materials as certain manufacturers have had supply disruptions related to the COVID-19 pandemic. If the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, the Company could experience future disruptions to its supply chain and operations and associated delays in the manufacturing and its clinical supply, which would adversely impact its preclinical and clinical development activities. However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.. Going Concern At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of December 31, 2021, the Company has generated an accumulated deficit of $188,904 since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. As of December 31, 2021, the Company’s cash, cash equivalents, short-term investments, and restricted cash were $48,341. Management believes that given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The Company has no committed sources of additional capital at this time and substantial additional financing will be needed by the Company to fund its operations. Management believes that it will be able to obtain additional funding through equity or debt financings, collaboration agreements, strategic partnerships and licensing arrangements, or other arrangements to fund its current operations and business strategy. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to raise additional capital, the Company could be forced to delay, reduce the scope of or eliminate its research and development programs or the Company may be required to relinquish rights to assets or preclinical programs that it might otherwise seek to develop independently, any of which could adversely affect its business prospects, or the Company may be unable to continue operations. The accompanying consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Significant Accounting Policies Cash, cash equivalents, and short-term investments The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s short-term investments have initial maturities of greater than three months from date of purchase. The Company classifies its marketable debt security investments as “available-for-sale” and carries them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. The Company records unrealized gains and losses on marketable debt securities in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or interest expense over the life of the of the underlying security. Realized gains and losses are included in other income, net. The Company uses the specific identification method to determine the cost of securities sold. Restricted cash As of December 31, 2021, the Company was required to maintain a balance of $8,000 in a blocked account in connection with Amendment No. 4 to the MidCap Credit Agreement (see Note 6); this amount is considered restricted cash and is presented within other noncurrent assets on the accompanying consolidated balance sheet at December 31, 2021. The Company also secures a standby letter of credit with a restricted certificate of deposit account as part of its Chicago lease agreement. The Company considers the restricted certificate of deposit account in the amount of $1,200 to be restricted cash because its use to the Company is contractually limited and presents the balance within other noncurrent assets on the accompanying consolidated balance sheet at December 31, 2021. Fair value of financial instruments The Company has estimated the fair value of its financial instruments. The carrying amounts for cash, cash equivalents, accounts receivable, and accounts payable approximate their fair value due to the relatively short-term nature of these instruments. The Company records short-term investments at their estimated fair value based on quoted market prices for identical or similar instruments. The Company believes that its long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates its fair value. Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. The Company places its cash, cash equivalents, and short-term investments with reputable financial institutions. The Company primarily invests its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss. For the year ended December 31, 2021, the Company’s revenue was generated from its collaborations with Ipsen and AbbVie. The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company’s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, Going Concern , for more information. The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution. The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance. Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three Property and equipment are reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No impairment losses were recorded from inception in December 2011 through December 31, 2021. Warrants The Company accounts for freestanding warrants within stockholder’s equity or as liabilities based on the characteristics and provisions of each instrument. The Company evaluates outstanding warrants in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity , and ASC 815, Derivatives and Hedging . If none of the criteria in the evaluation in these standards are met, the warrants are classified as a component of stockholders’ equity and initially recorded at their grant date fair value without subsequent remeasurement. Warrants that meet the criteria are classified as liabilities and remeasured to their fair value, estimated using the Black-Scholes option-pricing model, at the end of each reporting period with changes in the fair value of the liability recorded in other income (expense), net in the consolidated statements of operations. Revenue recognition Effective January 1, 2018, the Company adopted the provisions of ASC 606, Revenue from Contracts with Customers using the modified retrospective method for all contracts not completed as of the date of adoption. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: 1. Identify the contract with the customer. A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s intent and ability to pay, which is based on a variety of factors including the customer’s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment. 4. Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity’s performance, (ii) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset. Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition. For example, as discussed in Note 3, Collaborative Research and License Agreements , revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, Collaborative Research and License Agreements ) for the year ended December 31, 2021 was $(2,792) due primarily to the cumulative catchup adjustment (reduction) of revenue recorded in connection with a change in estimate that occurred during the third quarter of 2021. Licenses of intellectual property : If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. To date, the Company has not recognized any milestone payment revenue from any of its collaboration agreements. Royalties : For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements. Equity-based compensation The Company measures the cost of equity-based awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. The fair value of common stock option awards is affected by the valuation assumptions, including the expected volatility based on comparable market participants, expected term of the common stock option, risk-free interest rate, and expected dividends. For all equity-based awards, the fair value measurement date is the date of grant and the requisite service period is the period over which the recipient is required to provide service in exchange for the equity-based awards, which is generally the vesting period. Segments and geographic information The Company has determined it has one reporting segment. Disaggregating the Company’s operations is impracticable because the Company’s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All long-lived assets of the Company are located in the United States. Leases The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized on the balance sheet at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or to terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company’s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The lease payments used to determine the Company’s operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable. In addition, the Company’s lease arrangements may contain lease and non-lease components. The Company combines lease and non-lease components, which are accounted for together as a single lease component. Variable lease payments, such as real estate taxes and facility maintenance costs that are allocated by the lessor to the lessee and are not based on an index or a rate, are excluded from the measurement of the lease liability. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of twelve months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Costs for variable lease payments that are not included in the lease liability are recognized as expense as incurred. Research and development expense Research and development expenses are charged to expense as incurred in performing research and development activities in accordance with ASC 730, Research and Development . The costs include employee‑related expenses including salaries, benefits, and stock‑based compensation expense, costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on the Company’s behalf, the cost of purchasing lab supplies and non‑capital equipment used in preclinical and clinical activities and in manufacturing preclinical and clinical study materials, consultant fees, facility costs including rent, depreciation and maintenance expenses, fees for acquiring and maintaining licenses under third party licensing agreements, including any sublicensing or success payments made to the Company’s licensors, and overhead and other expenses directly related to research and development operations. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the accrual or prepaid is adjusted accordingly. The Company defers and capitalizes non-refundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. Income taxes The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2021 and 2020, the Company established a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized. Recent Accounting Pronouncements Not Yet Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13) . ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)—Effective Dates to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as “smaller reporting companies” as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements. |
Collaborative Research and Lice
Collaborative Research and License Agreements | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Collaborative Research and License Agreements | Collaborative Research and License Agreements Ipsen Collaboration Agreement Summary of Agreement On July 30, 2021 (the “Ipsen Effective Date”), the Company entered into a Collaboration, Option and License Agreement with Ipsen (the “Ipsen Collaboration Agreement”). Pursuant to the Ipsen Collaboration Agreement, the Company granted to Ipsen exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of Huntington’s disease and Angelman syndrome (each, an “Ipsen Collaboration Program”), respectively. Each such license (obtained in connection with the exercise of an Ipsen Option, as defined and discussed further below) would grant to Ipsen exclusive, royalty-bearing, sublicensable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Upon written notice to the Company, Ipsen may exercise its option during the corresponding collaboration program’s applicable option exercise period, (each, an “Ipsen Option Exercise Period”). As of the Ipsen Effective Date, the Company and Ipsen have agreed upon a development plan for each Ipsen Collaboration Program that describes the development activities and timelines required to advance each such Ipsen Collaboration Program through its first IND filing (each, an “Ipsen Development Plan”). The activities described in the Ipsen Development Plans are conducted under the supervision of the Ipsen Joint Steering Committee (the “Ipsen JSC”) consisting of three members from each of the Company and Ipsen. Under the terms of the Ipsen Collaboration Agreement, the Company will use commercially reasonable efforts to conduct discovery and development in two collaboration programs for Huntington’s disease (the “HD Program”) and Angelman syndrome (the “AS Program”) (the “Ipsen Development Activities”) respectively. The Company shall be solely responsible for all costs and expenses of conducting each Ipsen Collaboration Program through the selection of SNA therapeutic candidates for further development (“Ipsen Selection”), and Ipsen shall be responsible for all costs and expenses of all activities that are necessary to enable the first filing of an IND for each proposed product candidate. In the event that Ipsen exercises an option, Ipsen will be responsible for further development from the license effective date and commercialization of the corresponding licensed product. Following the completion of all Ipsen Development Activities for the Ipsen Selection (the “Ipsen First R&D Term Activities”), the Company is required to deliver to Ipsen a report that describes the results of the Ipsen First R&D Term Activities and identifies at least one SNA-based compound that satisfies certain criteria for such Ipsen Collaboration Program as determined by the Ipsen JSC (the “Ipsen First Option Data Package”). Following the delivery of the Ipsen First Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the “Ipsen First Option Exercise Period”) to exercise an option (each a “First Ipsen Option”) to obtain worldwide rights and license to the Company’s SNA technology and the Company’s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an “Ipsen Licensed Product”) that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement. In the event Ipsen (i) does not exercise the First Ipsen Option with respect to an Ipsen Collaboration Program, (ii) the Ipsen Collaboration Agreement has not expired or been terminated with respect to such Ipsen Collaboration Program, and (iii) Ipsen agrees to fully fund additional research activities for an Ipsen Collaboration Program through IND filing, the Company will be responsible for research and development activities for such Ipsen Collaboration Program through IND filing (the “Ipsen Second R&D Term Activities”). Following the completion of the Ipsen Second R&D Term Activities, the Company is required to deliver to Ipsen a report that describes the results of the Ipsen Second R&D Term Activities (the “Ipsen Second Option Data Package”). Following the delivery of the Ipsen Second Option Data Package for an Ipsen Collaboration Program, Ipsen will have the ability for a defined period of time (the “Ipsen Second Option Exercise Period”) to exercise an option (each a “Second Ipsen Option” and together with the First Ipsen Option, the “Ipsen Options”) to obtain worldwide rights and license to the Company’s SNA technology and the Company’s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any Ipsen Licensed Product” that results from such Ipsen Collaboration Program during the term of the Ipsen Collaboration Agreement. After Ipsen’s exercise of an Ipsen Option for an Ipsen Collaboration Program, the Company shall supply to Ipsen the licensed SNAs under current Good Manufacturing Practice, at the Company’s manufacturing cost pursuant to a clinical supply agreement to be negotiated by the Company and Ipsen in good faith following the Ipsen Effective Date and executed within twelve (12) months after the Ipsen Effective Date (the “Ipsen Supply Agreement”). The Ipsen Supply Agreement will provide for the transfer by the Company to Ipsen of all documents and information, and the provision by the Company of technical assistance and support, for Ipsen to manufacture or have manufactured by a third party contractor engaged by Ipsen the applicable licensed SNA to the extent it is intended to be actually used in the development and manufacture of the applicable licensed products. Under the terms of the Ipsen Collaboration Agreement, the Company received an upfront payment of $20,000 (the “Ipsen Upfront Payment”). If Ipsen exercises a First Ipsen Option, Ipsen is required to pay the Company the First Ipsen Option exercise fee of $10,000 for each Ipsen Collaboration Program. If Ipsen exercises a Second Ipsen Option, Ipsen is required to pay the Company the Second Ipsen Option exercise fee of $25,000 for each Ipsen Collaboration Program. Ipsen will pay a pre-clinical milestone payment of $5,000 for each Ipsen Collaboration Program upon achievement of such milestone regardless of whether an Ipsen Option is exercised. In addition to the option exercise fees and the pre-clinical milestones described above, if Ipsen exercises an Ipsen Option for an Ipsen Collaboration Program, development and regulatory milestones will be payable for that program upon the initiation of certain clinical trials and the filing for processing by the United States Food and Drug Administration (“FDA”) in the United States and by two additional regulators outside the United States of a marketing application for review, per the Ipsen Collaboration Program, with an aggregate total of up to $180,000 if both Ipsen Options are exercised. Commercial milestones will be payable for that Ipsen Collaboration Program upon first commercial sale of a licensed product in certain jurisdictions and the achievement of specified aggregate sales thresholds for all licensed products from that program, with an aggregate total of up to $762,000 if both Ipsen Options are exercised. In the event a therapeutic candidate subject to the Ipsen Collaboration Agreement results in commercial sales, the Company is eligible to receive tiered royalties at percentages ranging from the mid-single digits to the mid-teens on future net product sales of such commercialized therapeutic candidates. A percentage of the aforementioned payments will be due to Northwestern University upon receipt, pursuant to the terms of the Company’s existing license agreements with Northwestern University (see Note 15, Commitment and Contingencies, for more information on the Northwestern University License Agreements (as defined below)). In connection with the receipt of the Ipsen Upfront Payment, the Company paid a $3,000 license fee to Northwestern University under the terms of the Northwestern License Agreements. The Company’s obligations to conduct activities defined in the Ipsen Development Plan under the Ipsen Collaboration Agreement commenced on July 30, 2021 and continues, unless earlier terminated, until (a) the expiration of the later-to-expire Ipsen Option Exercise Period, if Ipsen does not exercise either Ipsen Option, or (b) the expiration of the last-to-expire royalty term for any licensed product in such country on a licensed product-by-licensed product and country-by-country basis, if Ipsen exercises one or both Ipsen Options. Upon expiration of the royalty term with respect to a particular licensed product in a country, the license for such product in such country will convert to a fully-paid, irrevocable and perpetual license. The Ipsen Collaboration Agreement also contains customary provisions for termination by either party, including by Ipsen for any or no reason in its entirety upon (90) days prior written notice and including in the event of breach of the Ipsen Collaboration Agreement, subject to cure, and by the Company upon a challenge of the licensed patents, subject, in certain cases, to customary reversion rights. Upon termination of the Ipsen Collaboration Agreement by the Company for Ipsen’s breach or bankruptcy, all licenses granted by the Company to Ipsen will terminate. The Ipsen Collaboration Agreement includes customary representations and warranties on behalf of both the Company and Ipsen. The Ipsen Collaboration Agreement also provides for customary mutual indemnities. In addition, the Ipsen Collaboration Agreement imposes certain exclusivity obligations on Ipsen and the Company, respectively, with respect to the development, use, manufacture and commercialization of oligonucleotide-based therapeutic targeting the same targets in the collaboration programs and/or certain other specific targets. Either party may assign the Ipsen Collaboration Agreement or delegate its obligations to an affiliate or to a successor to substantially all of the business to which the Ipsen Collaboration Agreement relates without the consent of the other party. Accounting Analysis The Company concluded that Ipsen is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the Ipsen Collaboration Agreement, the Company has identified two performance obligations, as follows: (1) the performance obligation related to the HD Program that includes (i) the Ipsen First R&D Term Activities related to the HD Program (the “Ipsen HD Program R&D Services”), (ii) Ipsen JSC services related to the HD Program during the Ipsen First Term (the “Ipsen HD Program JSC Services”), and (iii) activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date; and (2) the performance obligation related to the AS Program that includes (i) the Ipsen First R&D Term Activities related to the AS Program (the “Ipsen AS Program R&D Services”), (ii) Ipsen JSC services related to the AS Program during the Ipsen First Term (the “Ipsen AS Program JSC Services”), (iii) and activities related to the negotiation of the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date. The Company has concluded that the Ipsen HD Program R&D Services and the Ipsen AS Program R&D Services are not distinct from the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services, respectively. The Company has also concluded that the Ipsen HD Program JSC Services and the Ipsen AS Program JSC Services are not distinct from the activities related to entering the Ipsen Supply Agreements for each respective program. The Ipsen JSC provides oversight and management of the overall Ipsen Collaboration Agreement, and the members of the Ipsen JSC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The Ipsen JSC is meant to facilitate the early stage research being performed and coordinate the activities of both the Company and Ipsen. Further, the Ipsen JSC services are critical to the ongoing evaluation of the Ipsen Collaboration Programs and the drafting and evaluation of the Ipsen First Option Data Package. The Ipsen JSC will also provide oversight and management of the activities to enter into the Ipsen Supply Agreement. Accordingly, the Company’s participation on the Ipsen JSC is essential to Ipsen receiving value from the Ipsen HD Program R&D Services and the Ipsen AS Program R&D Services, and as such, (i) the Ipsen HD Program JSC Services, along with the Ipsen HD Program R&D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the “Ipsen HD Program Services”) and (ii) the Ipsen AS Program JSC Services along with the Ipsen AS Program R&D Services and the activities related to entering the Ipsen Supply Agreement within twelve months of the Ipsen Effective Date for that program are considered a single performance obligation (the “Ipsen AS Program Services”). As of the Ipsen Effective Date, the total transaction price was determined to be $20,000, consisting solely of the Ipsen Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the Ipsen Effective Date, there were no milestones included in the transaction price. The pre-clinical, development, regulatory, and commercial milestones were fully constrained due to the significant uncertainties surrounding such payments. The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Ipsen. The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore, they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December 31, 2021, the Company determined that any pre-clinical, development, regulatory, or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at December 31, 2021. The Company allocated the total transaction price to each of the two identified performance obligations under the Ipsen Collaboration Agreement based on an expected cost plus a margin approach, as follows: $10,793 of the transaction price allocated to the Ipsen HD Program Services and $9,207 of the transaction price allocated to the Ipsen AS Program Services. The Company will recognize revenue related to each of Ipsen HD Program Services and the Ipsen AS Program Services as those performance obligations are satisfied using an input method to measure progress for each of those performance obligations. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the activities for the Ipsen HD Program Services and the Ipsen AS Program Services. During the year ended December 31, 2021, the Company recognized revenue under the Ipsen Collaboration Agreement of approximately $2,309. As of December 31, 2021 , there was $17,691 of deferred revenue related to the Ipsen Collaboration Agreement, of which is $8,757 is classified as current and $8,934 is classified as noncurrent on the consolidated balance sheet. Deferred revenue under the Ipsen Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies its obligations under the Ipsen Collaboration Agreement, which the Company currently estimates to be over the next 30 to 39 months. AbbVie Collaboration Agreement Summary of Agreement On November 13, 2019 (the “AbbVie Effective Date”), the Company entered into a Collaboration, Option and License Agreement (the “AbbVie Collaboration Agreement”), with a wholly-owned subsidiary of Allergan plc, Allergan. On May 8, 2020, Allergan plc, including Allergan was acquired by AbbVie. Pursuant to the AbbVie Collaboration Agreement, the Company granted to AbbVie exclusive access and options to license SNA-based therapeutics arising from two collaboration programs related to the treatment of hair loss disorders (each, an “AbbVie Collaboration Program”). Under each such license (obtained in connection with the exercise of an AbbVie Option, as defined and discussed further below), the Company would grant to AbbVie exclusive, royalty-bearing, sublicensable, nontransferable, worldwide rights to develop, manufacture, use and commercialize such SNA therapeutics. Under the AbbVie Collaboration Agreement, the Company will use commercially reasonable efforts to conduct the AbbVie Collaboration Programs, each focused on one or more hair loss disorders to discover one or more SNA products that are directed to, bind to or inhibit one or more specific AbbVie Collaboration Program targets. As of the AbbVie Effective Date, the Company and AbbVie have agreed upon a development plan for each AbbVie Collaboration Program that describes the development activities and timelines required to advance such AbbVie Collaboration Program through its first IND filing (each, an “AbbVie Development Plan”). The activities described in the AbbVie Development Plan are conducted under the supervision of the AbbVie Joint Development Committee (the “AbbVie JDC”) consisting of three members from each of the Company and AbbVie. The Company is primarily responsible for performing early-stage discovery and preclinical activities (the “AbbVie Collaboration Program Initial Development Activities”) set forth in the AbbVie Development Plan for each AbbVie Collaboration Program and will be solely responsible for all costs and expenses related to the AbbVie Collaboration Program Initial Development Activities. AbbVie may elect, in its sole discretion and at its sole cost and expense, to conduct formulation assessment and in vivo testing as set forth in an AbbVie Development Plan. During the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program. In connection with the revised workplan for each AbbVie Collaboration Program, the Company expects to perform additional early stage discovery and preclinical activities to those set forth in the AbbVie Development Plan. As such, the Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program. Further changes to estimated additional efforts may be required in future periods should there be further revisions to the workplan for each AbbVie Collaboration Program. Following the completion of all AbbVie Initial Development Activities, the Company is required to deliver to AbbVie a report that describes the results of the AbbVie Initial Development Activities and identifies at least one SNA-based compound that satisfies certain criteria for such AbbVie Collaboration Program as determined by the AbbVie JDC (the “AbbVie Initial Development Report”). Following the delivery of the AbbVie Initial Development Report for an AbbVie Collaboration Program, AbbVie will have the ability for a defined period of time (the “AbbVie Initial Option Exercise Period”) to exercise an option (each an “AbbVie Option”) to obtain worldwide rights and license to the Company’s SNA technology and the Company’s interest in joint collaboration technology to make, have made, import, use, sell or offer for sale any product (each an “AbbVie Licensed Product”) that results from such AbbVie Collaboration Program during the term of the AbbVie Collaboration Agreement. At AbbVie’s sole option, AbbVie may extend the AbbVie Initial Option Exercise Period (the “AbbVie Option Extension”) and require the Company to perform IND-enabling activities described in the AbbVie Development Plan (the “AbbVie IND-Enabling Activities”), subject to the payment of additional consideration (“AbbVie Extension Exercise”). If AbbVie exercises the AbbVie Option Extension, the Company would be responsible for conducting the AbbVie IND-Enabling Activities and would be solely responsible for all costs and expenses associated with such activities. Upon completion of the AbbVie IND-Enabling Activities, the Company is required to deliver a report that describes the results of the AbbVie IND-Enabling Activities (the “AbbVie IND-Enabling Activities Data Package”) to AbbVie. Following the delivery of AbbVie IND-Enabling Activities Data Package, AbbVie will have the ability for a defined period of time (the “AbbVie Extended Option Exercise Period”) to exercise an AbbVie Option with respect to such AbbVie Collaboration Program. After the exercise of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie will be responsible for all development, manufacturing and commercialization activities, and costs and expense associated with such activities in connection with AbbVie Licensed Products arising from such AbbVie Collaboration Program. The Company’s obligation to conduct the activities defined in the AbbVie Development Plan under the AbbVie Collaboration Agreement commenced on November 13, 2019 and continues until the earlier of (i) the date AbbVie exercises an AbbVie Option, (ii) the date AbbVie abandons an AbbVie Collaboration Program and foregoes its AbbVie Option to that AbbVie Collaboration Program, or (iii) the fifth anniversary of the AbbVie Effective Date (the “AbbVie Research Term”). If the AbbVie Initial Option Exercise Period or AbbVie Extended Option Exercise Period is still in effect for an AbbVie Collaboration Program or if the Company has not delivered a complete AbbVie Initial Development Report or, if AbbVie made an AbbVie Extension Exercise for an AbbVie Collaboration Program, a complete AbbVie IND-Enabling Activities Data Package for such AbbVie Collaboration Program, as determined by the AbbVie JDC, then the AbbVie Research Term will automatically extend by one-year increments until such obligation is satisfied, but in no event past the seventh anniversary of the AbbVie Effective Date. Under the terms of the AbbVie Collaboration Agreement, the Company received a $25,000 upfront, non-refundable, non-creditable cash payment (the “AbbVie Upfront Payment”) related to the Company’s research and development costs for conducting the AbbVie Development Plan for two AbbVie Collaboration Programs, each focused on one or more targets, and certain options to obtain exclusive, worldwide licenses under certain intellectual property rights owned or controlled by the Company to develop, manufacture and commercialize certain products resulting from each such AbbVie Collaboration Programs. The option exercise fee during the AbbVie Initial Option Exercise Period is $10,000 per AbbVie Collaboration Program. If AbbVie elects to extend the AbbVie Initial Option Exercise Period, AbbVie is required to pay an additional fee of $10,000. If AbbVie elects to exercise its option during the AbbVie Extended Option Exercise Period, AbbVie must pay the Company the option exercise fee of $15,000. Following the exercise by AbbVie of an AbbVie Option with respect to an AbbVie Collaboration Program, AbbVie would be required to make certain milestone payments to the Company upon the achievement of specified development, product approval and launch, and commercial events, on an AbbVie Licensed Product by AbbVie Licensed Product basis. On an AbbVie Licensed Product by AbbVie Licensed Product basis, for the first AbbVie Licensed Product to achieve the associated milestone event, the Company is eligible to receive up to an aggregate of $55,000 for development milestone payments and $132,500 for product approval and launch milestone payments. The Company is also eligible for up to $175,000 in sales milestone payments on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, associated with aggregate worldwide sales. Certain product approval milestones are subject to certain reductions under specified circumstances, including for payments required to be made by AbbVie to obtain certain third-party intellectual property rights. In addition, to the extent there is any AbbVie Licensed Product, the Company would be entitled to receive tiered royalty payments of mid-single digits to the mid-teens percentage on future net worldwide product sales of such AbbVie Licensed Products, subject to certain reductions under specified circumstances. Royalties are due on a AbbVie Licensed Product by AbbVie Licensed Product and country by country basis from the date of the first commercial sale of each AbbVie Licensed Product in a country until the latest to occur of: (i) the expiration date in such country of the last to expire valid claim within the licensed intellectual property covering the manufacture, use or sale of such AbbVie Licensed Product in such country, (ii) the tenth anniversary of the first commercial sale of such AbbVie Licensed Product in such country, and (iii) the expiration of regulatory exclusivity for such AbbVie Licensed Product in such country. AbbVie may terminate the AbbVie Collaboration Agreement for any reason or no reason, either in its entirety or on an AbbVie Collaboration Program by AbbVie Collaboration Program basis, at any time on 90 days’ prior written notice to the Company. Unless earlier terminated, the term of the AbbVie Collaboration Agreement shall continue until (i) if both AbbVie Option Exercise Periods expire without AbbVie exercising either AbbVie Option, the expiration of the later to expire AbbVie Option Exercise Period, and (ii) if either or both AbbVie Options are exercised on an AbbVie Licensed Product by AbbVie Licensed Product and country-by-country basis, the expiration of the royalty term for such AbbVie Licensed Product in such country. Either party may terminate the AbbVie Collaboration Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations and such breach or default continues after the specified cure period. Termination of the AbbVie Collaboration Agreement for any reason will not release either party from any liability which, at the time of such termination, has already accrued to the other party or which is attributable to a period prior to such termination. In addition, termination of the AbbVie Collaboration Agreement will not preclude either party from pursuing any rights and remedies it may have under the agreement or at law or in equity with respect to any breach of the AbbVie Collaboration Agreement. If either party terminates the AbbVie Collaboration Agreement, the license and rights granted to AbbVie with respect to the terminated AbbVie Collaboration Program or AbbVie License Product shall terminate. Accounting Analysis The Company concluded that AbbVie is a customer in this arrangement, and as such the arrangement falls within the scope of the revenue recognition guidance. Under the AbbVie Collaboration Agreement, the Company has identified a single performance obligation that includes (i) the research and development activities during the AbbVie Research Term (the “AbbVie R&D Services”), and (ii) AbbVie Joint Development Committee services during the AbbVie Research Term (the “AbbVie JDC Services”). The Company has concluded that the AbbVie R&D Services is not distinct from the AbbVie JDC Services during the AbbVie Research Term. The AbbVie JDC provides oversight and management of the overall AbbVie Collaboration Agreement, and the members of the AbbVie JDC from the Company have specialized industry knowledge, particularly as it relates to SNA technology. The AbbVie JDC is meant to facilitate the early-stage research being performed and coordinate the activities of both the Company and AbbVie. Further, the AbbVie JDC services are critical to the ongoing evaluation of an AbbVie Collaboration Program and the drafting and evaluation of the AbbVie Initial Development Report and the AbbVie IND-Enabling Data Package. Accordingly, the Company’s participation on the AbbVie JDC is essential to AbbVie receiving value from the AbbVie R&D Services and as such, the AbbVie JDC Services along with the AbbVie R&D Services are considered one performance obligation (the “AbbVie Collaboration Program Services”). In addition, the Company has concluded that the option to purchase two development and commercialization licenses is considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement, and thus, not a performance obligation at the onset of the agreement. The consideration for these options will be accounted for when they are exercised. As of the AbbVie Effective Date, the total transaction price was determined to be $25,000, consisting solely of the AbbVie Upfront Payment. The Company also utilized the most likely amount method to estimate any development and regulatory milestone payments to be received. As of the AbbVie Effective Date, there were no milestones included in the transaction price. The milestones were fully constrained due to the significant uncertainties surrounding such payments. The Company considered the stage of development and the risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or AbbVie. The Company has determined that any commercial milestones and sales-based royalties will be recognized when the related sales occur and therefore they have also been excluded from the transaction price. The Company will re-evaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December 31, 2021, the Company determined that any development, regulatory or commercial milestones continue to be constrained and therefore the related milestone payments continue to be excluded from the transaction price at December 31, 2021. The Company will recognize revenue related to the AbbVie Collaboration Program Services as the performance obligation is satisfied using an input method to measure progress. The Company believes the input method that most accurately depicts the measure of progress is the actual hours incurred to date relative to projected hours to complete the research service. As discussed above, during the third quarter of 2021, the AbbVie JDC revised the AbbVie Initial Development Plan for each AbbVie Collaboration Program. As a result, the Company has increased its estimate of total hours to complete the research services, requiring an adjustment to cumulative revenue recognized (considered a change in estimate pursuant to ASC 606), which led to a full year revenue reversal of $(2,792) in the current year. During the year ended December 31, 2021, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $(2,792), reflecting the cumulative catchup adjustment (reduction) of revenue discussed above due to a change in estimate. The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement due to the revised workplan for each AbbVie Collaboration Program. These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the year ended December 31, 2021 as compared to the amount of revenue recognized at December 31, 2020, which led to revenue reversal in the current year period. During the year ended December 31, 2020, the Company recognized revenue under the AbbVie Collaboration Agreement of approximately $16,486. As of December 31, 2021, there was $11,135 of deferred revenue related to the AbbVie Collaboration Agreement, of which $8,560 is classified as current and $2,575 is classified as noncurrent on the consolidated balance sheet. Deferred revenue under the AbbVie Collaboration Agreement will be recognized as revenue in future periods as the Company satisfies it |
Supplemental Balance Sheet Info
Supplemental Balance Sheet Information | 12 Months Ended |
Dec. 31, 2021 | |
Supplemental Balance Sheet Information [Abstract] | |
Supplemental Balance Sheet Information | Supplemental Balance Sheet Information Prepaid expenses and other current assets December 31, 2021 2020 Prepaid clinical, contract research and manufacturing costs $ 2,484 $ 2,336 Prepaid insurance 763 694 Other 1,278 1,201 Prepaid expenses and other current assets $ 4,525 $ 4,231 Other noncurrent assets December 31, 2021 2020 Restricted cash $ 9,200 $ 1,200 Other 125 193 Other noncurrent assets $ 9,325 $ 1,393 Property and equipment, net December 31, 2021 2020 Scientific equipment $ 6,471 $ 5,476 Leasehold improvements — 192 Computers and software 60 46 Furniture and fixtures 30 30 Construction in process 33 119 Property and equipment, gross 6,594 5,863 Less: accumulated depreciation (2,667) (1,740) Property and equipment, net $ 3,927 $ 4,123 Depreciation and amortization expense was $1,123 and $766, for the years ended December 31, 2021 and 2020, respectively. Accrued expenses and other current liabilities December 31, 2021 2020 Accrued clinical, contract research and manufacturing costs $ 3,689 $ 1,372 Accrued restructuring costs 1,191 — Lease liability, current 459 223 Accrued payroll-related expenses 167 1,158 Accrued other expenses 958 772 Accrued expenses and other current liabilities $ 6,464 $ 3,525 |
Investments
Investments | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | InvestmentsAs of December 31, 2021 and 2020, the Company primarily invested its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The following table summarizes the contract maturity of the available-for-sale securities the Company held as of December 31, 2021: One year or less 100 % After one year but within two years — % Total 100 % All of the Company’s available-for-sale securities are available to the Company for use in its current operations. As a result, the Company categorizes all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at December 31, 2021 and 2020 were as follows: December 31, 2021 Amortized Costs Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Commercial paper $ 10,498 $ — $ (2) $ 10,496 $ 10,498 $ — $ (2) $ 10,496 December 31, 2020 Amortized Costs Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Commercial paper $ 15,992 $ 2 $ (3) $ 15,991 Corporate notes/bonds 29,227 72 (3) 29,296 U.S. Treasuries 2,251 2 — 2,253 U.S. Government agency securities 1,265 13 — 1,278 $ 48,735 $ 89 $ (6) $ 48,818 |
Debt
Debt | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Debt | Debt MidCap Credit Agreement On December 10, 2021, the Company entered into an amendment (“Amendment No. 4”) to the Company’s Credit and Security Agreement, dated as of September 25, 2020, as amended on October 21, 2020, July 30, 2021 and September 30, 2021, with MidCap Financial Trust, as agent (“MidCap”), and the lenders party thereto from time to time (as amended, the “MidCap Credit Agreement”), to prepay $10,000 of the Company’s outstanding loans under the MidCap Credit Agreement. Additionally, in connection with Amendment No. 4, the Company is required to maintain a balance of $20,000 in all accounts at Silicon Valley Bank, including $8,000 in a blocked account at Silicon Valley Bank. The balance of $8,000 in the blocked account at Silicon Valley Bank is restricted cash and is presented within other noncurrent assets on the accompanying consolidated balance sheet. The MidCap Credit Agreement provides for a secured term loan facility in an aggregate principal amount of up to $25,000 (the “MidCap Credit Facility”). The Company borrowed the first advance of $17,500 (“Tranche 1”) on September 25, 2020 (the “Closing Date”). Amendment No. 4 terminated the availability of the second advance of $7,500 (“Tranche 2”), effective as of December 9, 2021, that was previously available under the MidCap Credit Agreement subject to certain conditions. Tranche 1 bears interest at a floating rate equal to 6.25% per annum, plus the greater of (i) 1.50% or (ii) one-month LIBOR. Interest on each loan advance is due and payable monthly in arrears. Principal on each loan advance is payable in 36 equal monthly installments beginning October 1, 2022 until paid in full on October 1, 2025 (the “Maturity Date”). Prepayments of the loans under the MidCap Credit Agreement, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date and 1.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date and prior to the maturity date. In connection with Amendment No. 4, the early termination fee associated with the prepayment of $10,000 made in December 2021 was waived and if the remaining principal amount is repaid on or prior to March 31, 2022, the associated early termination fee for that prepayment will be waived. In connection with execution of the MidCap Credit Agreement, the Company paid MidCap a $125 origination fee. At the Maturity Date or on any earlier date on which all amounts advanced to the Company become due and payable in full, or are otherwise paid in full, the Company is required to pay an exit fee equal to 3.75% of the principal amount of all loans advanced to the Company under the MidCap Credit Agreement. Upon the advance of Tranche 1, the Company accrued $656 for the related exit fee. In connection with Amendment No. 4, if the remaining principal amount is repaid on or prior to March 31, 2022, a portion of the related exit fee that has not been earned by MidCap will be waived. The Company’s obligations under the MidCap Credit Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the MidCap Credit Agreement. The MidCap Credit Agreement contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The MidCap Credit Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, the agent and the lenders may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 2.0%. Total proceeds, net of fees and issuance costs, borrowed under Tranche 1 were $16,512. Fees and issuance costs of $332, as well as fees of $656 that are payable to MidCap at maturity of Tranche 1, are recorded as a reduction to the carrying amount of long-term debt on the Company’s balance sheet and will be amortized to interest expense through the maturity date of October 1, 2025 using the effective interest method. Fees and issuance costs of $73 attributed to the amount available to be borrowed under Tranche 2 were paid and recorded as deferred financing costs (other assets) and were amortized and recorded to interest expense in 2021 when it was determined that amounts under Tranche 2 would not be borrowed. As of December 31, 2021, deferred financing costs attributed to Tranche 2 are zero. As of December 31, 2021, the aggregate carrying value of the Company’s long-term debt is $6,873. As of December 31, 2021, the principal maturities of the Company’s long-term debt were as follows: December 31, 2021 2022 625 2023 2,500 2024 2,500 2025 1,875 Principal balance outstanding 7,500 less: unamortized discount and debt issuance costs (627) Long-term debt 6,873 Current portion 6,873 Noncurrent portion $ — The Company paid interest on the MidCap Credit Agreement of $1,375 and $252 during the years ended December 31, 2021 and 2020, respectively. The Company paid interest on the Hercules Loan Agreement (as discussed below) of $0 and $142 during the years ended December 31, 2021 and 2020, respectively. On March 15, 2022 the Company repaid all remaining outstanding obligations under the MidCap Credit Agreement. Refer to Note 17, Subsequent Events for more information. Hercules Loan Agreement On March 2, 2020, pursuant to the terms of the loan agreement with Hercules Technology Growth Capital (“Hercules”) and subsequent amendments thereto (the “Hercules Loan Agreement”), the Company repaid all remaining outstanding obligations under the Hercules Loan Agreement as of the maturity date, including the outstanding principal balance of $4,999 and the end of term fee of $100. |
Leases
Leases | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Leases | LeasesThe Company’s lease arrangements at December 31, 2021 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”), (ii) a lease for office space at a multi-tenant facility in Cambridge, Massachusetts that commenced in March 2019 and is cancelable at any time (the “Cambridge Lease”), and (iii) leases for office equipment (the “Office Equipment Leases”). Each of these leases are classified as operating leases. Due to the nature of the Cambridge Lease, the Company determined that this lease represented a short-term lease with an initial term of less than twelve months and, as such, the Cambridge Lease is not recorded on the balance sheet and related lease costs are recognized in the statement of operations as they are incurred. The Company has also elected to not record the Office Equipment Leases on the balance sheet since related payment amounts and lease costs are insignificant. Lease costs for the Office Equipment Leases are recognized in the statement of operations on a straight-line basis over the lease term. The Company’s lease arrangement for office and laboratory space at its former headquarters in Skokie, Illinois ended in February 2021 in accordance with the terms of that lease arrangement. Chicago Lease The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois (the “Chicago Lease”). The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate. The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes are subject to certain abatements. Upon execution of the Chicago Lease, the Company paid to the landlord the first installment of base rent and the estimated monthly amount of its pro rata share of taxes and its pro rata share of operating expenses in the aggregate amount of $87 which amount had been adjusted for the abatement as set forth in the lease agreement. The Company also paid the landlord a net amount of $697 toward tenant improvements. As part of the agreement for the Chicago Lease, the Company is required to maintain a standby letter of credit during the term of the lease, currently in the amount of $1,200 and subject to reduction over time, which is secured by a restricted certificate of deposit account and presented within other noncurrent assets on the Company’s consolidated balance sheet at December 31, 2021. The Company recognized a right of use asset of $8,931 and a lease liability of $8,147 on the Commencement Date. Because the rate implicit in the Chicago Lease is not readily determinable, the Company used its incremental borrowing rate of 8.3% on the Commencement Date to determine the present value of the lease payments over the Original Term. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. As of December 31, 2021, the Company determined it is not reasonably certain that the renewal option would be exercised. Skokie Lease In connection with the Company’s relocation of its headquarters from Skokie, Illinois to its new facility in Chicago, Illinois on July 1, 2020, the Company determined that the remaining useful life of the right of use asset underlying the Skokie Lease at June 30, 2020 was zero Information related to the Company’s operating lease asset and related operating lease liabilities were as follows: December 31, 2021 2020 Weighted-average remaining lease term 8.5 years 9.5 years Weighted-average discount rate 8.3 % 8.3 % The following table summarizes lease costs in the Company’s consolidated statement of operations: December 31, 2021 2020 Operating lease costs $ 1,306 $ 1,042 Variable lease costs 1,070 521 Short term lease costs 130 127 Total lease costs $ 2,506 $ 1,690 The Company made cash payments for operating leases of $2,134 and $2,244 during the years ended December 31, 2021 and 2020, respectively. Maturities of the Company’s lease liability as of December 31, 2021 were as follows: Years Ending December 31, Operating Leases 2022 1,067 2023 1,198 2024 1,235 2025 1,272 Thereafter 6,207 Total $ 10,979 Less: imputed interest (3,116) Total lease liability $ 7,863 Current operating lease liability $ 459 Noncurrent operating lease liability 7,404 Total lease liability $ 7,863 |
Restructuring
Restructuring | 12 Months Ended |
Dec. 31, 2021 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | RestructuringOn December 10, 2021, the Company announced its commitment to a plan to wind down the Company’s immuno-oncology program for cavrotolimod (AST-008) and the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. The Company intends to realign its research and development resources to support (i) the development of its preclinical program targeting SCN9A for neuropathic pain, (ii) the continued advancement of its partnered programs with Ipsen Biopharm Limited to develop SNA-based treatments in neuroscience targeting Huntington’s disease and Angelman syndrome, (iii) its continued advancement of its partnered program with AbbVie to develop SNA-based treatments for hair loss disorders, as well as (iv) the continued research and development of other undisclosed therapeutic product candidates. This plan resulted in a reduction in force where the Company eliminated approximately 50% of the Company’s existing workforce on a staggered basis through January 2022 as well as other cost-cutting measures. Notified employees were offered separation benefits, including severance payments and temporary healthcare coverage assistance. In most cases, the separation benefits were paid as a lump sum in January 2022. Certain of the notified employees had employment agreements which provided for separation benefits in the form of salary continuation; these benefits will be paid between February 2022 and January 2023. All of the severance costs represent cash expenditures. The Company expensed the following costs associated with these future termination benefit payments resulting from the strategic reduction in force: Year Ended December 31, 2021 Research and development expense $ 623 General and administrative expense 575 $ 1,198 |
Stockholders' Equity
Stockholders' Equity | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Preferred Stock The Company has 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding. Common Stock The Company has 200,000,000 shares of common stock, par value $0.0001, authorized. As of December 31, 2021 and December 31, 2020, the Company had 108,783,144 and 87,651,352 shares issued and outstanding, respectively. The holders of shares of the Company’s common stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company’s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of shares of the Company’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company’s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common stock. The outstanding shares of the Company’s common stock are fully paid and non-assessable. Registered Direct Offering On December 16, 2021, the Company completed a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers (the “Purchasers”) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of the Nasdaq Stock Market (the “Registered Direct Offering”), (i) an aggregate of 13,006,614 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 21,569,454 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 17,288,034 shares of Common Stock (the “Warrants”). The combined purchase price of each share of Common Stock and accompanying Warrant is $0.3326 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is $0.3316 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The per share exercise price for the Warrants is $0.2701, the closing bid price of the Company’s Common Stock on December 13, 2021. The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders’ equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were $11,478 and net proceeds after deducting the placement agent’s fees and other offering expenses paid or payable by the Company were $10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the “Registration Statement”). Each Warrant is exercisable for one share of Common Stock at an exercise price of $0.2701 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Refer to Note 17, Subsequent Events for more information on Pre-Funded Warrants. December 2019 Offering On December 23, 2019, the Company sold 10,000,000 shares of its common stock at the public offering price of $2.75 per share in an underwritten public offering for gross proceeds of $27,500 and estimated net proceeds of $25,344 after deducting underwriting discounts and commission and other offering expenses payable by the Company (the “December 2019 Offering”). In addition, the Company granted the underwriters a 30-day option to purchase an additional 1,500,000 shares of common stock. On January 6, 2020, the underwriters exercised such option with respect to 1,081,184 shares of common stock at the public offering price of $2.75 per share for additional gross proceeds of $2,973 and net proceeds of $2,766 after deducting underwriting discounts and commission and other offering expenses. The shares sold in the December 2019 Offering were sold pursuant to a registration statement on Form S-3 that was declared effective by the SEC on July 24, 2019. Common Stock Warrants In December 2021, 7,569,454 Pre-Funded Warrants were exercised for a total exercise price of $8, resulting in the issuance of 7,569,454 shares of common stock. As of December 31, 2021, Pre-Funded Warrants to purchase 14,000,000 shares of common stock at a price of $0.001 per share remain outstanding and Warrants to purchase 17,288,034 shares of common stock at a price of $0.2701 per share remain outstanding. The warrants are classified as equity. As of December 31, 2020, warrants to purchase 413,320 shares of common stock at a price of $3.00 per share that were issued in connection with a private placement offering of common stock in 2017 remained outstanding. These warrants expired unexercised as follows: 163,174 warrants expired on March 27, 2021, 132,884 expired on April 28, 2021, and 117,262 expired on May 3, 2021. These warrants were classified as a liability which was remeasured each period at fair value. See Note 13, Fair Value Measurements for more information on the fair value of the common stock warrant liability. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2021: Unrealized gains (losses) on short-term investments Total Balance at December 31, 2020 $ 83 $ 83 Other comprehensive loss before reclassifications (84) (84) Net gains reclassified from accumulated other comprehensive loss (1) (1) Net current period other comprehensive loss (85) (85) Balance at December 31, 2021 $ (2) $ (2) The net gain reclassified from accumulated other comprehensive loss during the year ended December 31, 2021 resulted from available-for-sale securities that were called prior to maturity. The basis on which the cost of the securities was determined was specific identification. Proceeds related to these sales were $4,000. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2020: Unrealized gains (losses) on short-term investments Total Balance at December 31, 2019 $ (27) $ (27) Other comprehensive income (loss) before reclassifications 107 107 Net losses reclassified from accumulated other comprehensive loss 3 3 Net current period other comprehensive income 110 110 Balance at December 31, 2020 $ 83 $ 83 |
Equity-Based Compensation
Equity-Based Compensation | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Equity-Based Compensation | Equity-Based Compensation 2017 Equity Incentive Plan On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 5,842,525 shares of Exicure common stock, which includes 2,169,905 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 3,683,817 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 4,600,000 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. As of December 31, 2021, the aggregate number of awards available for grant under the 2017 Plan was 3,904,367. On January 1, 2022, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 4,600,000 awards. Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above. Inducement Grant In May 2021, the Company granted stock options to purchase up to 600,000 shares of common stock as a material inducement to Brian C. Bock to enter into employment with the Company as the Company’s Chief Financial Officer (the “Inducement Grant”). The Inducement Grant, which was made pursuant to a stand-alone nonstatutory stock option agreement (the “Inducement Award Agreement”), was approved by the Compensation Committee, was awarded in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company’s 2017 Equity Incentive Plan and is subject to the terms and conditions of the Inducement Award Agreement. As such, any shares underlying the Inducement Grant are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. As of December 31, 2021, stock options to purchase up to 600,000 shares of common stock remained outstanding under the Inducement Grant. In connection with Mr. Bock’s resignation from the Company on February 4, 2022, the stock options underlying the Inducement Grant were forfeited. Employee Stock Purchase Plan The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 7,500 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. Each offering period is approximately six-months in duration and the first offering period began on November 16, 2020 and ended on May 14, 2021. During 2021, the Company issued 189,221 shares of common stock that were purchased under the ESPP. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 300,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. As of December 31, 2021, there were 1,014,666 shares available for issuance under the ESPP. On January 1, 2022, the number of shares of common stock available for issuance under the ESPP increased by 300,000 shares. Equity-based compensation expense is classified in the statements of operations as follows: Year Ended December 31, 2021 2020 Research and development expense $ 1,362 $ 878 General and administrative expense 1,577 1,306 $ 2,939 $ 2,184 Unamortized equity-based compensation expense at December 31, 2021 was $5,806, which is expected to be amortized over a weighted-average period of 2.8 years. The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below: Year Ended December 31, 2021 2020 Expected term 5.0 to 6.1 years 5.2 to 6.1 years Risk-free interest rate 0.36% to 1.12%; weighted avg. 1.05% 0.31% to 1.68%; weighted avg. 0.61% Expected volatility 81.7% to 83.6%; weighted avg. 82.6% 81.0% to 85.8%; weighted avg. 83.8% Forfeiture rate 5 % 5 % Expected dividend yield — % — % The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant. The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2021 and 2020 are summarized in the table below: Common Stock Options Granted During Period Ended: Fair Value of Underlying Common Stock Exercise Price of Common Stock Option Year ended December 31, 2021 $1.15 to $2.57; weighted avg. $1.87 $1.15 to $2.57; weighted avg. $1.87 Year ended December 31, 2020 $1.19 to $2.80; weighted avg. $1.89 $1.19 to $2.80; weighted avg. $1.93 The weighted-average grant date fair value of common stock options granted in the years ended December 31, 2021 and 2020 was $1.30 and $1.32 per common stock option, respectively. A summary of common stock option activity as of the periods indicated is as follows: Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding - December 31, 2020 7,227,296 $ 2.24 6.8 $ 1,719 Granted 4,427,586 1.87 Exercised (342,246) 1.60 Forfeited (1,367,863) 2.48 Outstanding - December 31, 2021 9,944,773 $ 2.06 7.0 $ — Exercisable - December 31, 2021 5,402,307 $ 2.18 5.4 $ — Vested and Expected to Vest - 9,635,719 $ 2.07 7.0 $ — The aggregate intrinsic value of common stock options exercised during the years ended December 31, 2021 and 2020 was $243 and $526, respectively. A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2020 — $ — Granted 734,000 1.49 Vested (35,750) 1.90 Forfeited (395,000) 1.31 Unvested balance - December 31, 2021 303,250 $ 1.67 The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. The restricted stock units granted during the 2021 period generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period. |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes Pre-tax loss before income taxes was $64,102 and $24,668 for the years ended December 31, 2021 and 2020, respectively, which consists entirely of losses in the U.S. and resulted in no provision for income tax expense during the years then ended. The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: Year Ended December 31, 2021 2020 Federal income tax expense at statutory rate $ (13,461) 21.0 % $ (5,180) 21.0 % State income tax expense at statutory rate (4,816) 7.5 (1,801) 7.3 Permanent differences 245 (0.4) 142 (0.6) Other (32) — — — Change in valuation allowance 18,064 (28.1) 6,839 (27.7) $ — — % $ — — % The Company’s effective income tax rate for the years ended December 31, 2021 and 2020 is 0% because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized. The significant components of the Company’s net deferred tax assets are as follows: December 31, 2021 2020 Deferred Tax Assets Net operating losses $ 42,769 $ 26,346 Tax credits 3,922 — Intangibles 134 152 Accrued expenses 1,331 810 Operating lease liability 2,253 2,333 Equity-based compensation 1,622 1,206 Deferred revenue 3,191 2,378 Other 54 54 Less: Valuation allowance (52,392) (30,406) Total deferred tax assets 2,884 2,873 Deferred Tax Liabilities Prepaid Expenses (308) (335) Fixed assets and other (298) (85) Right-of-use asset (2,278) (2,453) Total deferred tax liabilities (2,884) (2,873) Deferred taxes, net $ — $ — The Company has recorded a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized at December 31, 2021 and 2020. This determination is based on significant negative evidence, including: • Cumulative losses: The Company has been in a significant cumulative loss position since its inception in 2011. • Projected realization of net operating loss carry forward amounts: Projections of future pre-tax book loss and taxable losses based on the Company's recent actual performance and current industry data indicate it is more likely than not that the benefits will not be recognized. At December 31, 2021, the Company had a federal net operating loss carryforward of $150,329, of which $31,809 will begin to expire in 2035 and $118,520 which do not expire and may be carried forward indefinitely. At December 31, 2021, the Company had $149,789 of state net operating loss carryforwards which will begin to expire in 2027. At December 31, 2021 and 2020, the Company had no unrecognized tax benefits. The Company's estimate of the potential outcome of any uncertain tax positions is subject to management's assessment of relevant risks, facts and circumstances existing at that time. The Company evaluates uncertain tax positions to determine if it is more-likely-than-not that they would be sustained upon examination. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. |
Loss Per Common Share
Loss Per Common Share | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Loss Per Common Share | Loss Per Common Share Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2021 and 2020. The following is the computation of loss per common share for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Net loss $ (64,102) $ (24,668) Weighted-average basic and diluted common shares outstanding 88,617,332 87,203,588 Loss per share - basic and diluted $ (0.72) $ (0.28) The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period: December 31, 2021 2020 Options to purchase common stock 9,944,773 7,227,296 Restricted stock units 303,250 — Warrants to purchase common stock 31,288,034 413,320 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements ASC Topic 820, Fair Value Measurement , establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Assets measured at fair value on a recurring basis as of December 31, 2021 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 21,125 $ 21,125 $ — $ — Commercial paper 5,999 — 5,999 — Short-term investments: Commercial paper 4,497 — 4,497 — Total financial assets $ 31,621 $ 21,125 $ 10,496 $ — Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 24,586 $ 24,586 $ — $ — Short-term investments: Commercial paper 15,991 — 15,991 — Corporate notes/bonds 29,296 — 29,296 — U.S. Treasuries 2,253 — 2,253 — U.S. Government agency securities 1,278 — 1,278 — Total financial assets $ 73,404 $ 24,586 $ 48,818 $ — Liabilities Common stock warrant liability $ 15 $ — $ — $ 15 Total financial liabilities $ 15 $ — $ — $ 15 The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company’s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy. As of December 31, 2021, the Company’s common stock warrant liability was $0 and no warrants were outstanding underlying the common stock warrant liability (refer to Note 9, Stockholders’ Equity , for more information). The following is a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the years ended December 31, 2021 and 2020: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Common Stock Warrant Liability Balance at December 31, 2019 $ 414 Gain included in other income (expense), net (399) Balance at December 31, 2020 $ 15 Gain included in other income (expense), net (15) Balance at December 31, 2021 $ — |
Defined Contribution Plan
Defined Contribution Plan | 12 Months Ended |
Dec. 31, 2021 | |
Retirement Benefits [Abstract] | |
Defined Contribution Plan | Defined Contribution PlanExicure maintains a defined contribution savings plan for the benefit of its employees. Company contributions are determined under various formulas. The expense recognized for this plan was $402 and $257 for the years ended December 31, 2021 and 2020, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al. , Case No. 1:21-cv-0663. On February 4, 2021, Plaintiff filed an amended putative securities class action complaint. The amended complaint alleges that Messrs. Giljohann and Bock made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. On February 11, 2022, four members of the putative class moved the Court for appointment as lead plaintiff in the action pursuant to the Private Securities Litigation Reform Act of 1995. Two of those motions were withdrawn on February 25, 2022, and two remain pending. On February 16, 2022, the Court entered an order stating that defendants need not answer, or otherwise respond, until the Court enters an order appointing lead plaintiff and lead counsel, and the parties then submit a schedule to the Court for the filing of a further amended complaint and the timing of defendants’ answer or response. On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Messrs. Giljohann and Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al. , Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al. , Case No. 1:22-cv-01217. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri and Sim complaints (the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in its 2021 proxy statement regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties owed under state law. The Derivative Complaints also assert that Messrs. Giljohann and Bock are liable for contribution under the federal securities laws. The Puri complaint further asserts state law claims for unjust enrichment, abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seeks restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders. Leases Refer to Note 7, Leases , for a discussion of the commitments associated with the Company’s lease agreements. Northwestern University License Agreements |
Related-Party Transactions
Related-Party Transactions | 12 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related-Party Transactions | Related-Party TransactionsThe Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but, through April 30, 2021, served as a member of the Board. The Company recognized expense of $75 and $100 for the years ended December 31, 2021 and 2020 in connection with these consulting services in the accompanying consolidated statement of operations. The consulting agreement with this co-founder and former Board member expired on September 30, 2021 under the terms of the agreement and was not renewed. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events MidCap Credit Agreement On March 15, 2022, pursuant to the terms of the MidCap Credit Agreement, the Company repaid all remaining outstanding obligations under the MidCap Credit Agreement, including the outstanding principal balance of $7,500 and an exit fee of $506. Exercise of Pre-Funded Warrants On January 4, 2022 and January 21, 2022, the holder of the Pre-Funded Warrants exercised the right to purchase 7,500,000 shares and 6,500,000 shares, respectively, of the Company’s common stock. As a result, 14,000,000 aggregate shares of the Company’s common stock were issued upon such exercises with aggregate proceeds from totaling $14 such exercises. There are no remaining unexercised Pre-Funded Warrants as a result of such exercises in January 2022. Repricing of Outstanding and Unexercised Options On March 24, 2022, the Board unanimously approved the repricing of all outstanding and unexercised stock options granted under the 2015 Plan and 2017 Plan (the “Plans”) and held by current employees, executive officers, and directors of the Company (the “Eligible Stock Options”). The exercise price of the Eligible Stock Options will be reduced to the closing price of the Company’s common stock on April 1, 2022. Except for the modification to the exercise price of the Eligible Stock Options, all other terms and conditions of each of the Eligible Stock Options will remain in full force and effect. Pursuant to the Plans, the Board, as the administrator of the Plans, has discretionary authority, exercisable on such terms and conditions that it deems appropriate under the circumstances, to reduce the exercise price in effect for outstanding options under the Plans. In approving the repricing, the Board considered the impact of the current exercise prices of outstanding stock options on the incentives provided to employees and directors, the lack of retention value provided by the outstanding stock options to employees and directors, and the impact of such options on the capital structure of the Company. As of March 24, 2022, there are currently 6,996,741 stock options outstanding under the Plans, and all of the Company’s outstanding stock options have exercise prices in excess of the current fair market value of the Company’s common stock, which is why the Board made the determination to deem all outstanding and unexercised stock options held by current employees, executive officers, and directors as Eligible Stock Options. Matthias Schroff, the Company’s Chief Executive Officer, and Elias Papadimas, the Company’s Chief Financial Officer, hold Eligible Stock Options exercisable into an aggregate of 881,200 and 375,417 shares of the Company’s common stock, respectively. Non-employee directors Jeffrey Cleland, Elizabeth Garofalo, Bali Muralidhar and James Sulat hold Eligible Stock Options exercisable into an aggregate of 115,079, 150,000, 115,079 and 93,386 shares of the Company’s common stock, respectively. The Company expects to record the impact of the option repricing in the quarter ending June 30, 2022. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of presentation | Basis of PresentationThe accompanying consolidated financial statements as of December 31, 2021 and 2020, and for the years then ended, have been presented in conformity with generally accepted accounting principles in the United States (“GAAP”). |
Principles of consolidation | Principles of Consolidation The accompanying consolidated financial statements include the accounts of Exicure, Inc. and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation. |
Significant Risks and Uncertainties | Significant Risks and Uncertainties As discussed in Note 3, Collaborative Research and License Agreements , revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, Collaborative Research and License Agreements ) for the year ended December 31, 2021 reflects the cumulative catchup adjustment (reduction) of revenue of recorded in connection with a change in estimate that occurred during the third quarter of 2021. The Company currently estimates significant additional efforts will be required to satisfy the performance obligation under the AbbVie Collaboration Agreement. These increased estimated efforts in connection with the change in workplan resulted in less progress occurring relative to the increased estimate of total project hours to complete the research services during the year ended December 31, 2021 as compared to the amount of revenue recognized at December 31, 2020, which led to a full year revenue reversal of $(2,792) in the current year. Due to uncertainties inherent in the estimation process, it is at least reasonably possible that estimated efforts required to complete the research services under the AbbVie Collaboration Agreement will be further revised in the near-term which may result in additional adjustments (reductions of revenue) in future periods. As discussed in Note 2, Significant Accounting Policies — Revenue Recognition , determining the estimate of total project hours used to recognize revenue for the Company’s collaboration agreements requires significant judgment and any changes to those estimates may have a significant impact on the amount and timing of revenue recognition for the Ipsen Collaboration Agreement or the AbbVie Collaboration Agreement (each, as defined in Note 3, Collaborative Research and License Agreements ) in future periods. COVID-19 Risks and Uncertainties In response to the ongoing COVID-19 pandemic, the Company has taken and continues to take active measures designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company continues to monitor closely the developments and continue to take active measures to protect the health of its employees and their families, and its communities. Its on-site activities continue with protocols for safely accessing and working within its facilities. While the Company continues to conduct research and development activities, the COVID-19 pandemic has impacted, and may continue to impact, certain of its early-stage discovery efforts. The Company is working closely with its third-party manufacturers and other partners to manage its supply chain activities and mitigate potential disruptions as a result of the COVID-19 pandemic. The Company has observed minor delays in receipt of key chemicals, reagents and materials as certain manufacturers have had supply disruptions related to the COVID-19 pandemic. If the COVID-19 pandemic continues to persist for an extended period of time and impacts essential distribution systems such as FedEx and postal delivery, the Company could experience future disruptions to its supply chain and operations and associated delays in the manufacturing and its clinical supply, which would adversely impact its preclinical and clinical development activities. However, if the COVID-19 pandemic continues to persist for an extended period of time, the Company could experience further significant disruptions to its clinical and preclinical development timelines, which would adversely affect its business, financial condition, results of operations and growth prospects. In addition, the Company is subject to other challenges and risks specific to its business and its ability to execute on its business plan and strategy, as well as risks and uncertainties common to companies in the biotechnology industry with research and development operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of its product candidates; delays or problems in obtaining clinical supply, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing its intellectual property rights; and the challenges of complying with applicable regulatory requirements. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties.. |
Use of estimates | Use of EstimatesThe preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates |
Cash, cash equivalents and short-term investments | Cash, cash equivalents, and short-term investments The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s short-term investments have initial maturities of greater than three months from date of purchase. The Company classifies its marketable debt security investments as “available-for-sale” and carries them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. The Company records unrealized gains and losses on marketable debt securities in other comprehensive income (loss) as a component of stockholders’ equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or interest expense over the life of the of the underlying security. Realized gains and losses are included in other income, net. The Company uses the specific identification method to determine the cost of securities sold. |
Restricted cash | Restricted cash As of December 31, 2021, the Company was required to maintain a balance of $8,000 in a blocked account in connection with Amendment No. 4 to the MidCap Credit Agreement (see Note 6); this amount is considered restricted cash and is presented within other noncurrent assets on the accompanying consolidated balance sheet at December 31, 2021. The Company also secures a standby letter of credit with a restricted certificate of deposit account as part of its Chicago lease agreement. The Company considers the restricted certificate of deposit account in the amount of $1,200 to be restricted cash because its use to the Company is contractually limited and presents the balance within other noncurrent assets on the accompanying consolidated balance sheet at December 31, 2021. |
Fair value of financial instruments | Fair value of financial instruments The Company has estimated the fair value of its financial instruments. The carrying amounts for cash, cash equivalents, accounts receivable, and accounts payable approximate their fair value due to the relatively short-term nature of these instruments. The Company records short-term investments at their estimated fair value based on quoted market prices for identical or similar instruments. The Company believes that its long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates its fair value. |
Concentrations of credit risk and other risks and uncertainties | Concentrations of credit risk and other risks and uncertainties Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments, and accounts receivable. The Company places its cash, cash equivalents, and short-term investments with reputable financial institutions. The Company primarily invests its excess cash in debt instruments of corporations, the U.S. Treasury, financial institutions, and U.S. government agencies with strong credit ratings and an investment grade rating at or above a long-term rating of Aa3/AA- and a short-term rating of P1/A1. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. The Company periodically reviews and modifies these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss. For the year ended December 31, 2021, the Company’s revenue was generated from its collaborations with Ipsen and AbbVie. The Company is currently not profitable and no assurance can be provided that it will ever be profitable. The Company’s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues. See also Note 1, Going Concern , for more information. |
Property and equipment | Property and equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from three |
Warrants | Warrants The Company accounts for freestanding warrants within stockholder’s equity or as liabilities based on the characteristics and provisions of each instrument. The Company evaluates outstanding warrants in accordance with Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity , and ASC 815, Derivatives and Hedging |
Revenue recognition | Revenue recognition Effective January 1, 2018, the Company adopted the provisions of ASC 606, Revenue from Contracts with Customers using the modified retrospective method for all contracts not completed as of the date of adoption. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: 1. Identify the contract with the customer. A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights and obligations regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer’s intent and ability to pay, which is based on a variety of factors including the customer’s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer. 2. Identify the performance obligations in the contract. Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. 3. Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment. 4. Allocate the transaction price to performance obligations in the contract. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. 5. Recognize revenue when or as the Company satisfies a performance obligation. The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity’s performance, (ii) the entity’s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity’s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset. Revenue allocated to performance obligations relating to provision of research and development activities is recognized as the performance obligations are satisfied using an input method to measure progress, based on an estimate of the percentage of completion of the project based on the actual hours incurred on the project as a percentage of the total expected project hours. The determination of the percentage of completion requires management to estimate the total expected project hours. A detailed estimate of the total expected project hours is re-assessed every reporting period based on the latest project plan and discussions with project teams. If a change in facts or circumstances occurs, the estimate will be adjusted and the revenue will be recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate would be recognized as an adjustment to revenue in the period in which the change in estimate occurs. Determining the estimate of total project hours requires significant judgment and may have a significant impact on the amount and timing of revenue recognition. For example, as discussed in Note 3, Collaborative Research and License Agreements , revenue recognized under the AbbVie Collaboration Agreement (as defined in Note 3, Collaborative Research and License Agreements ) for the year ended December 31, 2021 was $(2,792) due primarily to the cumulative catchup adjustment (reduction) of revenue recorded in connection with a change in estimate that occurred during the third quarter of 2021. Licenses of intellectual property : If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment. To date, the Company has not recognized any milestone payment revenue from any of its collaboration agreements. Royalties : For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements. |
Equity-based compensation | Equity-based compensation The Company measures the cost of equity-based awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. The fair value of common stock option awards is affected by the valuation assumptions, including the expected volatility based on comparable market participants, expected term of the common stock option, risk-free interest rate, and expected dividends. For all equity-based awards, the fair value measurement date is the date of grant and the requisite service period is the period over which the recipient is required to provide service in exchange for the equity-based awards, which is generally the vesting period. |
Segments and geographic information | Segments and geographic informationThe Company has determined it has one reporting segment. Disaggregating the Company’s operations is impracticable because the Company’s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment. All long-lived assets of the Company are located in the United States. |
Leases | Leases The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized on the balance sheet at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or to terminate the lease when it is reasonably certain that the Company will exercise that option. The Company uses the implicit interest rate when readily determinable and uses the Company’s incremental borrowing rate when the implicit rate is not readily determinable based upon the information available at the commencement date in determining the present value of the lease payments. The lease payments used to determine the Company’s operating lease assets may include lease incentives, stated rent increases and escalation clauses linked to rates of inflation when determinable. In addition, the Company’s lease arrangements may contain lease and non-lease components. The Company combines lease and non-lease components, which are accounted for together as a single lease component. Variable lease payments, such as real estate taxes and facility maintenance costs that are allocated by the lessor to the lessee and are not based on an index or a rate, are excluded from the measurement of the lease liability. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of twelve months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease. Costs for variable lease payments that are not included in the lease liability are recognized as expense as incurred. |
Research and development expense | Research and development expense Research and development expenses are charged to expense as incurred in performing research and development activities in accordance with ASC 730, Research and Development . The costs include employee‑related expenses including salaries, benefits, and stock‑based compensation expense, costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on the Company’s behalf, the cost of purchasing lab supplies and non‑capital equipment used in preclinical and clinical activities and in manufacturing preclinical and clinical study materials, consultant fees, facility costs including rent, depreciation and maintenance expenses, fees for acquiring and maintaining licenses under third party licensing agreements, including any sublicensing or success payments made to the Company’s licensors, and overhead and other expenses directly related to research and development operations. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the accrual or prepaid is adjusted accordingly. The Company defers and capitalizes non-refundable advance payments made by the Company for research and development activities until the related goods are received or the related services are performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. |
Income taxes | Income taxes The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2021 and 2020, the Company established a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized. |
Recent accounting pronouncements | Recent Accounting Pronouncements Not Yet Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13) . ASU 2016-13 is a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. ASU 2016-13 requires that credit losses on financial assets measured at amortized cost be determined using an expected loss model, instead of the current incurred loss model, and requires that credit losses related to available-for-sale debt securities be recorded through an allowance for credit losses and limited to the amount by which carrying value exceeds fair value. ASU 2016-13 also requires enhanced disclosure of credit risk associated with financial assets. The effective date of ASU 2016-13 was deferred by ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842)—Effective Dates to the annual period beginning after December 15, 2022 for companies that (i) meet the definition of an SEC filer and (ii) are eligible as “smaller reporting companies” as such term is defined by the SEC, with early adoption permitted. The Company is currently assessing the impact of adoption of ASU 2016-13 to its consolidated financial statements. |
Fair value measurements | The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company’s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level 2 of the fair value hierarchy. |
Collaborative Research and Li_2
Collaborative Research and License Agreements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Research and Development [Abstract] | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable | The following table presents changes in the balances of the Company’s contract liabilities (in thousands): Deferred Revenue Balance at January 1, 2021 Additions Revenue Deferred Revenue Balance at December 31, 2021 Ipsen Collaboration Agreement $ — $ 20,000 $ (2,309) $ 17,691 AbbVie Collaboration Agreement $ 8,343 $ — $ 2,792 $ 11,135 Total $ 8,343 $ 20,000 $ 483 $ 28,826 |
Supplemental Balance Sheet In_2
Supplemental Balance Sheet Information (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Supplemental Balance Sheet Information [Abstract] | |
Schedule of Prepaid and Other Current Assets | Prepaid expenses and other current assets December 31, 2021 2020 Prepaid clinical, contract research and manufacturing costs $ 2,484 $ 2,336 Prepaid insurance 763 694 Other 1,278 1,201 Prepaid expenses and other current assets $ 4,525 $ 4,231 |
Schedule of Other Assets, Noncurrent | Other noncurrent assets December 31, 2021 2020 Restricted cash $ 9,200 $ 1,200 Other 125 193 Other noncurrent assets $ 9,325 $ 1,393 |
Property, Plant and Equipment | Property and equipment, net December 31, 2021 2020 Scientific equipment $ 6,471 $ 5,476 Leasehold improvements — 192 Computers and software 60 46 Furniture and fixtures 30 30 Construction in process 33 119 Property and equipment, gross 6,594 5,863 Less: accumulated depreciation (2,667) (1,740) Property and equipment, net $ 3,927 $ 4,123 |
Schedule of Accrued Liabilities | Accrued expenses and other current liabilities December 31, 2021 2020 Accrued clinical, contract research and manufacturing costs $ 3,689 $ 1,372 Accrued restructuring costs 1,191 — Lease liability, current 459 223 Accrued payroll-related expenses 167 1,158 Accrued other expenses 958 772 Accrued expenses and other current liabilities $ 6,464 $ 3,525 |
Investments (Tables)
Investments (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
Investment | The following table summarizes the contract maturity of the available-for-sale securities the Company held as of December 31, 2021: One year or less 100 % After one year but within two years — % Total 100 % |
Debt Securities, Available-for-sale | The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of cash equivalents and available-for-sale securities by type of security at December 31, 2021 and 2020 were as follows: December 31, 2021 Amortized Costs Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Commercial paper $ 10,498 $ — $ (2) $ 10,496 $ 10,498 $ — $ (2) $ 10,496 December 31, 2020 Amortized Costs Gross Unrealized Holding Gains Gross Unrealized Holding Losses Fair Value Commercial paper $ 15,992 $ 2 $ (3) $ 15,991 Corporate notes/bonds 29,227 72 (3) 29,296 U.S. Treasuries 2,251 2 — 2,253 U.S. Government agency securities 1,265 13 — 1,278 $ 48,735 $ 89 $ (6) $ 48,818 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Principal Maturities of Long-term Debt | As of December 31, 2021, the principal maturities of the Company’s long-term debt were as follows: December 31, 2021 2022 625 2023 2,500 2024 2,500 2025 1,875 Principal balance outstanding 7,500 less: unamortized discount and debt issuance costs (627) Long-term debt 6,873 Current portion 6,873 Noncurrent portion $ — |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Leases [Abstract] | |
Schedule of Operating Leases, Additional Information | Information related to the Company’s operating lease asset and related operating lease liabilities were as follows: December 31, 2021 2020 Weighted-average remaining lease term 8.5 years 9.5 years Weighted-average discount rate 8.3 % 8.3 % |
Lease Costs | The following table summarizes lease costs in the Company’s consolidated statement of operations: December 31, 2021 2020 Operating lease costs $ 1,306 $ 1,042 Variable lease costs 1,070 521 Short term lease costs 130 127 Total lease costs $ 2,506 $ 1,690 |
Schedule of Future Minimum Rental Payments | Maturities of the Company’s lease liability as of December 31, 2021 were as follows: Years Ending December 31, Operating Leases 2022 1,067 2023 1,198 2024 1,235 2025 1,272 Thereafter 6,207 Total $ 10,979 Less: imputed interest (3,116) Total lease liability $ 7,863 Current operating lease liability $ 459 Noncurrent operating lease liability 7,404 Total lease liability $ 7,863 |
Restructuring (Tables)
Restructuring (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Restructuring and Related Activities [Abstract] | |
Schedule of Restructuring by Type of Cost | The Company expensed the following costs associated with these future termination benefit payments resulting from the strategic reduction in force: Year Ended December 31, 2021 Research and development expense $ 623 General and administrative expense 575 $ 1,198 |
Stockholders' Equity Stockholde
Stockholders' Equity Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income (Loss) | The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2021: Unrealized gains (losses) on short-term investments Total Balance at December 31, 2020 $ 83 $ 83 Other comprehensive loss before reclassifications (84) (84) Net gains reclassified from accumulated other comprehensive loss (1) (1) Net current period other comprehensive loss (85) (85) Balance at December 31, 2021 $ (2) $ (2) The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2020: Unrealized gains (losses) on short-term investments Total Balance at December 31, 2019 $ (27) $ (27) Other comprehensive income (loss) before reclassifications 107 107 Net losses reclassified from accumulated other comprehensive loss 3 3 Net current period other comprehensive income 110 110 Balance at December 31, 2020 $ 83 $ 83 |
Equity-Based Compensation (Tabl
Equity-Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Equity-Based Compensation Expense Classification in Statement of Operations | Equity-based compensation expense is classified in the statements of operations as follows: Year Ended December 31, 2021 2020 Research and development expense $ 1,362 $ 878 General and administrative expense 1,577 1,306 $ 2,939 $ 2,184 |
Assumptions Used to Determine Fair Value of Common Stock Option Grants | In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below: Year Ended December 31, 2021 2020 Expected term 5.0 to 6.1 years 5.2 to 6.1 years Risk-free interest rate 0.36% to 1.12%; weighted avg. 1.05% 0.31% to 1.68%; weighted avg. 0.61% Expected volatility 81.7% to 83.6%; weighted avg. 82.6% 81.0% to 85.8%; weighted avg. 83.8% Forfeiture rate 5 % 5 % Expected dividend yield — % — % The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2021 and 2020 are summarized in the table below: Common Stock Options Granted During Period Ended: Fair Value of Underlying Common Stock Exercise Price of Common Stock Option Year ended December 31, 2021 $1.15 to $2.57; weighted avg. $1.87 $1.15 to $2.57; weighted avg. $1.87 Year ended December 31, 2020 $1.19 to $2.80; weighted avg. $1.89 $1.19 to $2.80; weighted avg. $1.93 |
Common Stock Option Activity | A summary of common stock option activity as of the periods indicated is as follows: Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding - December 31, 2020 7,227,296 $ 2.24 6.8 $ 1,719 Granted 4,427,586 1.87 Exercised (342,246) 1.60 Forfeited (1,367,863) 2.48 Outstanding - December 31, 2021 9,944,773 $ 2.06 7.0 $ — Exercisable - December 31, 2021 5,402,307 $ 2.18 5.4 $ — Vested and Expected to Vest - 9,635,719 $ 2.07 7.0 $ — |
Restricted Stock Unit Awards Activity | A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2020 — $ — Granted 734,000 1.49 Vested (35,750) 1.90 Forfeited (395,000) 1.31 Unvested balance - December 31, 2021 303,250 $ 1.67 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Income Tax Disclosure [Abstract] | |
Schedule of Effective Income Tax Rate Reconciliation | The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows: Year Ended December 31, 2021 2020 Federal income tax expense at statutory rate $ (13,461) 21.0 % $ (5,180) 21.0 % State income tax expense at statutory rate (4,816) 7.5 (1,801) 7.3 Permanent differences 245 (0.4) 142 (0.6) Other (32) — — — Change in valuation allowance 18,064 (28.1) 6,839 (27.7) $ — — % $ — — % |
Schedule of Deferred Tax Assets and Liabilities | The significant components of the Company’s net deferred tax assets are as follows: December 31, 2021 2020 Deferred Tax Assets Net operating losses $ 42,769 $ 26,346 Tax credits 3,922 — Intangibles 134 152 Accrued expenses 1,331 810 Operating lease liability 2,253 2,333 Equity-based compensation 1,622 1,206 Deferred revenue 3,191 2,378 Other 54 54 Less: Valuation allowance (52,392) (30,406) Total deferred tax assets 2,884 2,873 Deferred Tax Liabilities Prepaid Expenses (308) (335) Fixed assets and other (298) (85) Right-of-use asset (2,278) (2,453) Total deferred tax liabilities (2,884) (2,873) Deferred taxes, net $ — $ — |
Loss Per Common Share (Tables)
Loss Per Common Share (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Earnings Per Share [Abstract] | |
Computation of Loss Per Common Share | The following is the computation of loss per common share for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Net loss $ (64,102) $ (24,668) Weighted-average basic and diluted common shares outstanding 88,617,332 87,203,588 Loss per share - basic and diluted $ (0.72) $ (0.28) |
Antidilutive Securities | December 31, 2021 2020 Options to purchase common stock 9,944,773 7,227,296 Restricted stock units 303,250 — Warrants to purchase common stock 31,288,034 413,320 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Assets measured at fair value on a recurring basis as of December 31, 2021 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 21,125 $ 21,125 $ — $ — Commercial paper 5,999 — 5,999 — Short-term investments: Commercial paper 4,497 — 4,497 — Total financial assets $ 31,621 $ 21,125 $ 10,496 $ — Assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 24,586 $ 24,586 $ — $ — Short-term investments: Commercial paper 15,991 — 15,991 — Corporate notes/bonds 29,296 — 29,296 — U.S. Treasuries 2,253 — 2,253 — U.S. Government agency securities 1,278 — 1,278 — Total financial assets $ 73,404 $ 24,586 $ 48,818 $ — Liabilities Common stock warrant liability $ 15 $ — $ — $ 15 Total financial liabilities $ 15 $ — $ — $ 15 |
Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis | The following is a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the years ended December 31, 2021 and 2020: Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Common Stock Warrant Liability Balance at December 31, 2019 $ 414 Gain included in other income (expense), net (399) Balance at December 31, 2020 $ 15 Gain included in other income (expense), net (15) Balance at December 31, 2021 $ — |
Description of Business and B_2
Description of Business and Basis of Presentation (Details) ft² in Thousands, $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($)ft² | |
Error Corrections and Prior Period Adjustments | |
Facility size (in square feet) | ft² | 30 |
Accumulated deficit | $ 188,904 |
Cash, cash equivalents, short-term investments, and restricted cash | 48,341 |
AbbVie Collaboration Agreement | Collaborative Arrangement | |
Error Corrections and Prior Period Adjustments | |
Cumulative catch-up adjustments to revenue, change in estimate | $ (2,792) |
Significant Accounting Polici_3
Significant Accounting Policies (Details) | 12 Months Ended | 121 Months Ended | ||
Dec. 31, 2021USD ($)segment | Dec. 31, 2021USD ($) | Dec. 10, 2021USD ($) | Dec. 31, 2020USD ($) | |
Property, Plant and Equipment [Line Items] | ||||
Restricted cash | $ 9,200,000 | $ 9,200,000 | $ 1,200,000 | |
Certificate of deposit | $ 1,200,000 | 1,200,000 | ||
Impairment losses | $ 0 | |||
Number of reporting segments | segment | 1 | |||
Number of operating segments | segment | 1 | |||
AbbVie Collaboration Agreement | Collaborative Arrangement | ||||
Property, Plant and Equipment [Line Items] | ||||
Cumulative catch-up adjustments to revenue, change in estimate | $ (2,792,000) | |||
Minimum | ||||
Property, Plant and Equipment [Line Items] | ||||
Estimated useful lives | 3 years | |||
Maximum | ||||
Property, Plant and Equipment [Line Items] | ||||
Estimated useful lives | 7 years | |||
MidCap Credit Agreement | ||||
Property, Plant and Equipment [Line Items] | ||||
Restricted cash | $ 8,000,000 |
Collaborative Research and Li_3
Collaborative Research and License Agreements (Details) $ in Thousands | Jul. 30, 2021USD ($)agreementperformanceObligation | Nov. 13, 2019USD ($)agreementperformanceObligationlicense | Feb. 17, 2019USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Deferred revenue | $ 28,826 | $ 8,343 | ||||
Deferred revenue, current | 17,317 | 8,343 | ||||
Deferred revenue, noncurrent | 11,509 | 0 | ||||
Ipsen Collaboration Agreement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration agreement, number of performance obligations | performanceObligation | 2 | |||||
Deferred revenue | 17,691 | 0 | ||||
Ipsen Collaboration Agreement | Ipsen HD | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Transaction price allocated | 10,793 | |||||
Ipsen Collaboration Agreement | Ipsen AS | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Transaction price allocated | 9,207 | |||||
Ipsen Collaboration Agreement | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Number of collaboration programs | agreement | 2 | |||||
Proceeds from collaborators | $ 20,000 | |||||
Pre-clinical milestone payment amount | 5,000 | |||||
Development and regulatory milestone payment amount | 180,000 | |||||
Commercial milestone payment amount | 762,000 | |||||
Collaboration agreement, licensing fees incurred | $ 3,000 | |||||
Collaboration agreement, termination notice period | 90 days | |||||
Transaction price allocated | $ 20,000 | |||||
Collaboration revenue | 2,309 | |||||
Deferred revenue | 17,691 | |||||
Deferred revenue, current | 8,757 | |||||
Deferred revenue, noncurrent | $ 8,934 | |||||
Ipsen Collaboration Agreement | Collaborative Arrangement | Exercise Period One | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration option exercise fee | 10,000 | |||||
Ipsen Collaboration Agreement | Collaborative Arrangement | Exercise Period Two | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration option exercise fee | $ 25,000 | |||||
Ipsen Collaboration Agreement | Minimum | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Estimated timing of revenue recognition | 30 months | |||||
Ipsen Collaboration Agreement | Maximum | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Estimated timing of revenue recognition | 39 months | |||||
AbbVie Collaboration Agreement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration agreement, number of performance obligations | performanceObligation | 1 | |||||
Deferred revenue | $ 11,135 | 8,343 | ||||
Collaboration agreement, number of development and commercialization licenses with option to purchase | license | 2 | |||||
AbbVie Collaboration Agreement | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Number of collaboration programs | agreement | 2 | |||||
Collaboration option exercise fee | $ 10,000 | |||||
Collaboration revenue | 16,486 | |||||
Deferred revenue | 11,135 | |||||
Deferred revenue, current | 8,560 | |||||
Deferred revenue, noncurrent | 2,575 | |||||
Non-refundable upfront payment received for research agreement | 25,000 | |||||
Collaboration option exercise fee | $ 10,000 | |||||
Termination period upon written notice | 90 days | |||||
Cumulative catch-up adjustments to revenue, change in estimate | $ (2,792) | |||||
AbbVie Collaboration Agreement | Minimum | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Deferred revenue, current | 8,343 | |||||
Estimated timing of revenue recognition | 21 months | |||||
AbbVie Collaboration Agreement | Maximum | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Estimated timing of revenue recognition | 24 months | |||||
Development milestone payment | $ 55,000 | |||||
Product approval and launch milestone payment | 132,500 | |||||
Sales milestone payment | 175,000 | |||||
Dermelix License Agreement | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration revenue | $ 0 | $ 127 | ||||
Deferred revenue | $ 0 | |||||
Non-refundable upfront payment received for research agreement | $ 1,000 | |||||
Collaboration development expenses | $ 1,000 | |||||
Development and Commercialization License | AbbVie Collaboration Agreement | Collaborative Arrangement | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Collaboration option exercise fee | $ 15,000 |
Collaborative Research and Li_4
Collaborative Research and License Agreements - Other Current Liabilities (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2021USD ($) | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Deferred Revenue Balance at January 1, 2021 | $ 8,343 |
Additions | 20,000 |
Revenue (Recognized) Reversed | 483 |
Deferred Revenue Balance at December 31, 2021 | 28,826 |
Ipsen Collaboration Agreement | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Deferred Revenue Balance at January 1, 2021 | 0 |
Additions | 20,000 |
Revenue (Recognized) Reversed | (2,309) |
Deferred Revenue Balance at December 31, 2021 | 17,691 |
AbbVie Collaboration Agreement | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |
Deferred Revenue Balance at January 1, 2021 | 8,343 |
Additions | 0 |
Revenue (Recognized) Reversed | 2,792 |
Deferred Revenue Balance at December 31, 2021 | $ 11,135 |
Supplemental Balance Sheet In_3
Supplemental Balance Sheet Information - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Supplemental Balance Sheet Information [Abstract] | ||
Prepaid clinical, contract research and manufacturing costs | $ 2,484 | $ 2,336 |
Prepaid insurance | 763 | 694 |
Other | 1,278 | 1,201 |
Prepaid expenses and other current assets | $ 4,525 | $ 4,231 |
Supplemental Balance Sheet In_4
Supplemental Balance Sheet Information - Noncurrent Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Supplemental Balance Sheet Information [Abstract] | ||
Restricted cash | $ 9,200 | $ 1,200 |
Other | 125 | 193 |
Other noncurrent assets | $ 9,325 | $ 1,393 |
Supplemental Balance Sheet In_5
Supplemental Balance Sheet Information - Property and Equipment, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 6,594 | $ 5,863 |
Less: accumulated depreciation | (2,667) | (1,740) |
Property and equipment, net | 3,927 | 4,123 |
Depreciation and amortization | 1,123 | 766 |
Scientific equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 6,471 | 5,476 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 0 | 192 |
Computers and software | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 60 | 46 |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 30 | 30 |
Construction in process | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 33 | $ 119 |
Supplemental Balance Sheet In_6
Supplemental Balance Sheet Information - Accrued Expense and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Supplemental Balance Sheet Information [Abstract] | ||
Accrued clinical, contract research and manufacturing costs | $ 3,689 | $ 1,372 |
Accrued restructuring costs | 1,191 | 0 |
Lease liability, current | 459 | 223 |
Accrued payroll-related expenses | 167 | 1,158 |
Accrued other expenses | 958 | 772 |
Accrued expenses and other current liabilities | $ 6,464 | $ 3,525 |
Investments - Contract Maturity
Investments - Contract Maturity of Available for Sale Securities (Details) | 12 Months Ended |
Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |
One year or less | 100.00% |
After one year but within two years | 0.00% |
Total | 100.00% |
Investments - Debt Securities,
Investments - Debt Securities, Available for sale (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Costs | $ 10,498 | $ 48,735 |
Gross Unrealized Holding Gains | 0 | 89 |
Gross Unrealized Holding Losses | (2) | (6) |
Fair Value | 10,496 | 48,818 |
Commercial paper | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Costs | 10,498 | 15,992 |
Gross Unrealized Holding Gains | 0 | 2 |
Gross Unrealized Holding Losses | (2) | (3) |
Fair Value | $ 10,496 | 15,991 |
Corporate notes/bonds | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Costs | 29,227 | |
Gross Unrealized Holding Gains | 72 | |
Gross Unrealized Holding Losses | (3) | |
Fair Value | 29,296 | |
U.S. Treasuries | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Costs | 2,251 | |
Gross Unrealized Holding Gains | 2 | |
Gross Unrealized Holding Losses | 0 | |
Fair Value | 2,253 | |
U.S. Government agency securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Amortized Costs | 1,265 | |
Gross Unrealized Holding Gains | 13 | |
Gross Unrealized Holding Losses | 0 | |
Fair Value | $ 1,278 |
Debt - Narrative (Details)
Debt - Narrative (Details) $ in Thousands | Dec. 10, 2021USD ($) | Sep. 25, 2020USD ($) | Mar. 02, 2020USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Oct. 01, 2022installmentPayment |
Debt Instrument [Line Items] | ||||||
Restricted cash | $ 9,200 | $ 1,200 | ||||
Proceeds from long-term borrowing | $ 0 | 17,500 | ||||
Exit fee, percentage | 3.75% | |||||
Long-term debt | $ 6,873 | |||||
Repayment of long-term debt | 10,000 | 4,999 | ||||
MidCap Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Covenant, minimum cash balance | $ 20,000 | |||||
Covenant, minimum cash balance, blocked account | 8,000 | |||||
Restricted cash | 8,000 | |||||
Loan processing fee | $ 125 | |||||
Interest paid | 1,375 | 252 | ||||
Hercules Loan Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Interest paid | $ 0 | $ 142 | ||||
Secured Debt | MidCap Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Repayments of debt | $ 10,000 | |||||
Aggregate principal amount | $ 25,000 | |||||
Interest rate, stated percentage | 6.25% | |||||
Floating interest rate (as a percent) | 1.50% | |||||
Interest rate, increase (decrease) | 2.00% | |||||
Secured Debt | MidCap Credit Agreement | Scenario, Forecast | ||||||
Debt Instrument [Line Items] | ||||||
Number of monthly installment payments | installmentPayment | 36 | |||||
Secured Debt | MidCap Credit Agreement | Debt Instrument, Redemption, Period One | ||||||
Debt Instrument [Line Items] | ||||||
Early termination fee, percentage | 3.00% | |||||
Secured Debt | MidCap Credit Agreement | Debt Instrument, Redemption, Period Two | ||||||
Debt Instrument [Line Items] | ||||||
Early termination fee, percentage | 1.00% | |||||
Secured Debt | MidCap Credit Agreement - Tranche 1 | ||||||
Debt Instrument [Line Items] | ||||||
Proceeds from long-term borrowing | $ 17,500 | |||||
Debt instrument, fee amount | 656 | |||||
Proceeds net of issuance costs | 16,512 | |||||
Unamortized debt issuance costs | 332 | |||||
Secured Debt | MidCap Credit Agreement - Tranche 2 | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | 7,500 | |||||
Unamortized debt issuance costs | $ 73 | |||||
Secured Debt | Hercules Technology Growth Capital | Loans Payable | ||||||
Debt Instrument [Line Items] | ||||||
Repayment of long-term debt | $ 4,999 | |||||
Payment for end of term fee | $ 100 |
Debt - Principal Maturities of
Debt - Principal Maturities of Long-Term Debt (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Debt Disclosure [Abstract] | ||
2022 | $ 625 | |
2023 | 2,500 | |
2024 | 2,500 | |
2025 | 1,875 | |
Principal balance outstanding | 7,500 | |
less: unamortized discount and debt issuance costs | (627) | |
Long-term debt | 6,873 | |
Current portion | 6,873 | $ 0 |
Noncurrent portion | $ 0 | $ 16,589 |
Leases - Narrative (Details)
Leases - Narrative (Details) ft² in Thousands, $ in Thousands | Jul. 01, 2020USD ($)ft²extensionPeriod | Jun. 30, 2020 | Jun. 30, 2020USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) |
Lessee, Lease, Description [Line Items] | |||||
Right-of-use asset | $ 7,950 | $ 8,606 | |||
Operating lease, liability | 7,863 | ||||
Amortization of right-of-use asset | 656 | 681 | |||
Operating lease payments | $ 2,134 | $ 2,244 | |||
Chicago | |||||
Lessee, Lease, Description [Line Items] | |||||
Operating lease area | ft² | 30 | ||||
Operating lease, contract term | 10 years | ||||
Operating lease, number of extensions | extensionPeriod | 2 | ||||
Operating lease, renewal term | 5 years | ||||
Operating lease, annual rent payment | $ 1,113 | ||||
Operating lease, base rent annual percentage increase | 3.00% | ||||
Operating lease, estimated rental payment over lease term | $ 12,761 | ||||
Operating lease, rental payment adjusted for abatement | 87 | ||||
Payments for tenant improvements | 697 | ||||
Letters of credit outstanding | 1,200 | ||||
Right-of-use asset | 8,931 | ||||
Operating lease, liability | $ 8,147 | ||||
Operating lease, discount rate | 8.30% | ||||
Skokie | |||||
Lessee, Lease, Description [Line Items] | |||||
Operating lease, remaining useful life | 0 years | ||||
Amortization of right-of-use asset | $ 211 |
Leases - Right of Use Asset Inf
Leases - Right of Use Asset Information (Details) | Dec. 31, 2021 | Dec. 31, 2020 |
Leases [Abstract] | ||
Weighted-average remaining lease term | 8 years 6 months | 9 years 6 months |
Weighted-average discount rate | 8.30% | 8.30% |
Leases - Lease Costs (Details)
Leases - Lease Costs (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Leases [Abstract] | ||
Operating lease costs | $ 1,306 | $ 1,042 |
Variable lease costs | 1,070 | 521 |
Short term lease costs | 130 | 127 |
Total lease costs | $ 2,506 | $ 1,690 |
Leases - Schedule of Future Min
Leases - Schedule of Future Minimum Rental Payments (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Leases [Abstract] | ||
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] | Accrued expenses and other current liabilities | Accrued expenses and other current liabilities |
2022 | $ 1,067 | |
2023 | 1,198 | |
2024 | 1,235 | |
2025 | 1,272 | |
Thereafter | 6,207 | |
Total | 10,979 | |
Less: imputed interest | (3,116) | |
Total lease liability | 7,863 | |
Current operating lease liability | 459 | $ 223 |
Noncurrent operating lease liability | $ 7,404 | $ 7,959 |
Restructuring (Details)
Restructuring (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Restructuring Cost and Reserve [Line Items] | ||
Future termination benefit payments | $ 1,198 | |
Accrued restructuring costs | 1,191 | $ 0 |
Research and development expense | ||
Restructuring Cost and Reserve [Line Items] | ||
Future termination benefit payments | 623 | |
General and administrative expense | ||
Restructuring Cost and Reserve [Line Items] | ||
Future termination benefit payments | $ 575 |
Stockholders' Equity - Current
Stockholders' Equity - Current Capitalization (Details) | Dec. 31, 2021votePerShare$ / sharesshares | Dec. 31, 2020$ / sharesshares |
Equity [Abstract] | ||
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Common stock, shares outstanding (in shares) | 108,783,144 | 87,651,352 |
Common stock, shares issued (in shares) | 108,783,144 | 87,651,352 |
Common stock, voting rights for each share | votePerShare | 1 |
Stockholders' Equity - Register
Stockholders' Equity - Registered Direct Offering (Details) - USD ($) $ / shares in Units, $ in Thousands | Dec. 16, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Class of Stock [Line Items] | |||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Exercise price (in dollars per share) | $ 3 | ||
Warrant term | 5 years | ||
Gross proceeds | $ 11,478 | ||
Net proceeds | $ 10,226 | ||
Ownership percentage limitation | 4.99% | ||
Ownership percentage limitation at election of purchaser | 9.99% | ||
Pre-Funded Warrants | |||
Class of Stock [Line Items] | |||
Warrants issued in sale of stock (in shares) | 21,569,454 | ||
Exercise price (in dollars per share) | $ 0.001 | ||
Warrant | |||
Class of Stock [Line Items] | |||
Warrants issued in sale of stock (in shares) | 17,288,034 | ||
Exercise price (in dollars per share) | $ 0.2701 | ||
Common Stock and Accompanying Warrant | |||
Class of Stock [Line Items] | |||
Purchase price (in dollars per share) | 0.3326 | ||
Pre-Funded Warrants and Accompanying Warrant | |||
Class of Stock [Line Items] | |||
Purchase price (in dollars per share) | $ 0.3316 | ||
Common Stock | |||
Class of Stock [Line Items] | |||
Shares issued in sale of stock (in shares) | 13,006,614 | ||
Common stock, par value (in dollars per share) | $ 0.0001 |
Stockholders' Equity - 2019 Sto
Stockholders' Equity - 2019 Stock Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands | Jan. 06, 2020 | Dec. 23, 2019 | Dec. 31, 2021 | Dec. 31, 2020 |
Class of Stock [Line Items] | ||||
Proceeds from common stock offering | $ 11,486 | $ 2,973 | ||
Common Stock Issued December 2019 | ||||
Class of Stock [Line Items] | ||||
Issuance of common stock and warrants, net (in shares) | 10,000,000 | |||
Price per share in sale of stock (in dollars per share) | $ 2.75 | |||
Proceeds from common stock offering | $ 27,500 | |||
Proceeds from issuance of common stock, net | $ 25,344 | |||
Over-Allotment Option | ||||
Class of Stock [Line Items] | ||||
Issuance of common stock and warrants, net (in shares) | 1,081,184 | |||
Price per share in sale of stock (in dollars per share) | $ 2.75 | |||
Proceeds from common stock offering | $ 2,973 | |||
Proceeds from issuance of common stock, net | $ 2,766 | |||
Shares issued in sale of stock (in shares) | 1,500,000 |
Stockholders' Equity - Common S
Stockholders' Equity - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | |||||
Dec. 31, 2021 | Dec. 16, 2021 | May 03, 2021 | Apr. 28, 2021 | Mar. 27, 2021 | Dec. 31, 2020 | |
Class of Stock [Line Items] | ||||||
Exercise price (in dollars per share) | $ 3 | |||||
Pre-Funded Warrants | ||||||
Class of Stock [Line Items] | ||||||
Warrants exercised (in shares) | 7,569,454 | |||||
Proceeds from warrant exercises | $ 8 | |||||
Shares issued for exercise of warrants (in shares) | 7,569,454 | |||||
Number of shares called by warrants (in shares) | 14,000,000 | |||||
Exercise price (in dollars per share) | $ 0.001 | |||||
Warrant | ||||||
Class of Stock [Line Items] | ||||||
Number of shares called by warrants (in shares) | 17,288,034 | |||||
Exercise price (in dollars per share) | $ 0.2701 | |||||
Private Placement | ||||||
Class of Stock [Line Items] | ||||||
Number of shares called by warrants (in shares) | 413,320 | |||||
Expiration of warrants (in shares) | 117,262 | 132,884 | 163,174 |
Stockholders' Equity - Accumula
Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Stockholders equity, beginning balance | $ 61,506 | $ 80,747 |
Other comprehensive income (loss) before reclassifications | (84) | 107 |
Net (gains) losses reclassified from accumulated other comprehensive loss | (1) | 3 |
Net current period other comprehensive income | (85) | 110 |
Stockholders equity, ending balance | 11,232 | 61,506 |
Accumulated Other Comprehensive Income (Loss) | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Stockholders equity, beginning balance | 83 | (27) |
Net current period other comprehensive income | (85) | 110 |
Stockholders equity, ending balance | (2) | 83 |
Unrealized gains (losses) on short-term investments | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | ||
Stockholders equity, beginning balance | 83 | (27) |
Other comprehensive income (loss) before reclassifications | (84) | 107 |
Net (gains) losses reclassified from accumulated other comprehensive loss | (1) | 3 |
Net current period other comprehensive income | (85) | 110 |
Stockholders equity, ending balance | $ (2) | $ 83 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
Gross realized gains | $ 23 | |
Gross realized losses | 6 | |
Proceeds from sales of available-for-sale debt securities | $ 4,000 | $ 9,404 |
Equity-Based Compensation - Nar
Equity-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 12 Months Ended | |||
May 31, 2021 | Sep. 30, 2017 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 22, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Options granted in period (in shares) | 4,427,586 | ||||
Options outstanding (in shares) | 9,944,773 | 7,227,296 | |||
Compensation cost not yet recognized | $ 5,806 | ||||
Compensation expense recognition period | 2 years 9 months 18 days | ||||
Weighted-average grant date fair value (in dollars per share) | $ 1.30 | $ 1.32 | |||
Intrinsic value of options exercised | $ 243 | $ 526 | |||
Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of shares available for grant (in shares) | 300,000 | ||||
Number of additional shares allowable annually under the plan (in shares) | 300,000 | ||||
Percentage of outstanding shares allowable as annual increase | 0.30% | ||||
Increase in number of shares available for grant | 1,014,666 | ||||
Employee Stock | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Maximum ESPP contribution rate as a percentage of compensation | 15.00% | ||||
Maximum number of shares per employee in purchase period (in shares) | 7,500 | ||||
Maximum contribution amount | $ 25 | ||||
ESPP purchase price as a percentage of market price | 85.00% | ||||
Offering period duration | 6 months | ||||
Issuance of common stock-ESPP (in shares) | 189,221 | ||||
Restricted stock units | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period | 4 years | ||||
Number of shares issued for each vested restricted stock unit (in shares) | 1 | ||||
Exicure, Inc. 2017 Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of shares authorized (in shares) | 5,842,525 | ||||
Number of shares available for grant (in shares) | 3,904,367 | 2,169,905 | |||
Potential maximum additional shares (in shares) | 4,600,000 | ||||
Percentage of common stock outstanding | 5.00% | ||||
Exicure, Inc. 2017 Equity Incentive Plan | Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of shares available for grant (in shares) | 4,600,000 | ||||
Expiration period | 10 years | ||||
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period | 48 months | ||||
Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period | 48 months | ||||
Exicure OpCo 2015 Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of shares available for grant (in shares) | 3,683,817 | ||||
Share-based Compensation Award, Tranche One | Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Vesting percentage | 25.00% | ||||
Share-based Compensation Award, Tranche Two | Initial Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Vesting percentage | 2.08% | ||||
Share-based Compensation Award, Tranche Two | Subsequent Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Vesting percentage | 2.08% | ||||
Non-employee Director | Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period | 36 months | ||||
Non-employee Director | Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Award vesting period | 12 months | ||||
Non-employee Director | Exicure OpCo 2015 Equity Incentive Plan | Initial Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Vesting percentage | 2.77% | ||||
Non-employee Director | Exicure OpCo 2015 Equity Incentive Plan | Subsequent Employee Stock Option | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Vesting percentage | 8.30% | ||||
Chief Financial Officer | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Options granted in period (in shares) | 600,000 | ||||
Options outstanding (in shares) | 600,000 |
Equity-Based Compensation - Sch
Equity-Based Compensation - Schedule of Compensation Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 2,939 | $ 2,184 |
Research and development expense | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | 1,362 | 878 |
General and administrative expense | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 1,577 | $ 1,306 |
Equity-Based Compensation - Ass
Equity-Based Compensation - Assumptions Used for Fair Value Measurement (Details) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Forfeiture rate | 5.00% | 5.00% |
Expected dividend yield | 0.00% | 0.00% |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term | 5 years | 5 years 2 months 12 days |
Risk-free interest rate | 0.36% | 0.31% |
Expected volatility | 81.70% | 81.00% |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term | 6 years 1 month 6 days | 6 years 1 month 6 days |
Risk-free interest rate | 1.12% | 1.68% |
Expected volatility | 83.60% | 85.80% |
Weighted Average | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free interest rate | 1.05% | 0.61% |
Expected volatility | 82.60% | 83.80% |
Equity-Based Compensation - Fai
Equity-Based Compensation - Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares | Dec. 31, 2021 | Dec. 31, 2020 |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair Value of Underlying Common Stock (in dollars per share) | $ 1.15 | $ 1.19 |
Exercise Price of Common Stock Option (in dollars per share) | 1.15 | 1.19 |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair Value of Underlying Common Stock (in dollars per share) | 2.57 | 2.80 |
Exercise Price of Common Stock Option (in dollars per share) | 2.57 | 2.80 |
Weighted Average | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair Value of Underlying Common Stock (in dollars per share) | 1.87 | 1.89 |
Exercise Price of Common Stock Option (in dollars per share) | $ 1.87 | $ 1.93 |
Equity-Based Compensation - S_2
Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Options | ||
Shares outstanding, beginning period (in shares) | 7,227,296 | |
Granted (in shares) | 4,427,586 | |
Exercised (in shares) | (342,246) | |
Forfeited (in shares) | (1,367,863) | |
Shares outstanding, ending period (in shares) | 9,944,773 | 7,227,296 |
Exercisable (in shares) | 5,402,307 | |
Vested and expected to vest, shares (in shares) | 9,635,719 | |
Weighted-Average Exercise Price | ||
Weighted-average exercise price, beginning period (in dollars per share) | $ 2.24 | |
Weighted-Average exercise price, granted (in dollars per share) | 1.87 | |
Weighted-average exercise price, exercised (in dollars per share) | 1.60 | |
Weighted-Average exercise price, forfeited (in dollars per share) | 2.48 | |
Weighted-average exercise price, ending period (in dollars per share) | 2.06 | $ 2.24 |
Exercisable, weighted average exercise price (in usd per share) | 2.18 | |
Vested and expected to vest, weighted average exercise price (in usd per share) | $ 2.07 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] | ||
Weighted-Average Remaining Contractual Term (years) | 7 years | 6 years 9 months 18 days |
Exercisable, weighted-average remaining contractual term | 5 years 4 months 24 days | |
Vested and expected to vest, weighted average remaining contractual term | 7 years | |
Aggregate Intrinsic Value (thousands) | $ 0 | $ 1,719 |
Exercisable, aggregate intrinsic value | 0 | |
Vested and expected to vest, aggregate intrinsic value | $ 0 |
Equity-Based Compensation - RSU
Equity-Based Compensation - RSU Activity (Details) | 12 Months Ended |
Dec. 31, 2021$ / sharesshares | |
Restricted Stock Units | |
Forfeited (in shares) | shares | (1,367,863) |
Weighted-Average Grant Date Fair Value | |
Forfeited (in dollars per share) | $ / shares | $ 2.48 |
Restricted stock units | |
Restricted Stock Units | |
Unvested balance - beginning of period (in shares) | shares | 0 |
Granted (in shares) | shares | 734,000 |
Vested (in shares) | shares | (35,750) |
Forfeited (in shares) | shares | (395,000) |
Unvested balance - end of period (in shares) | shares | 303,250 |
Weighted-Average Grant Date Fair Value | |
Unvested balance - beginning of period (in dollars per share) | $ / shares | $ 0 |
Granted (in dollars per share) | $ / shares | 1.49 |
Vested (in dollars per share) | $ / shares | 1.90 |
Forfeited (in dollars per share) | $ / shares | 1.31 |
Unvested balance - end of period (in dollars per share) | $ / shares | $ 1.67 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Operating Loss Carryforwards [Line Items] | ||
Net loss | $ 64,102,000 | $ 24,668,000 |
Provision for income taxes | $ 0 | $ 0 |
Effective tax rate | 0.00% | 0.00% |
Unrecognized tax benefits | $ 0 | $ 0 |
Federal | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforward | 150,329,000 | |
Net operating loss carryforwards, subject to expiration | 31,809,000 | |
Net operating loss carryforwards, not subject to expiration | 118,520,000 | |
State | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforward | $ 149,789,000 |
Income Taxes - Effective Income
Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Effective Income Tax Rate Reconciliation, Amount [Abstract] | ||
Federal income tax expense at statutory rate | $ (13,461,000) | $ (5,180,000) |
State income tax expense at statutory rate | (4,816,000) | (1,801,000) |
Permanent differences | 245,000 | 142,000 |
Other | (32,000) | 0 |
Change in valuation allowance | 18,064,000 | 6,839,000 |
Provision for income tax expense | $ 0 | $ 0 |
Effective Income Tax Rate Reconciliation, Percent [Abstract] | ||
Federal income tax expense at statutory rate | 21.00% | 21.00% |
State income tax expense at statutory rate | 7.50% | 7.30% |
Permanent differences | (0.40%) | (0.60%) |
Other | 0.00% | 0.00% |
Change in valuation allowance | (28.10%) | (27.70%) |
Effective tax rate | 0.00% | 0.00% |
Income Taxes - Deferred Tax Ass
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Deferred Tax Assets | ||
Net operating losses | $ 42,769 | $ 26,346 |
Tax credits | 3,922 | 0 |
Intangibles | 134 | 152 |
Accrued expenses | 1,331 | 810 |
Operating lease liability | 2,253 | 2,333 |
Equity-based compensation | 1,622 | 1,206 |
Deferred revenue | 3,191 | 2,378 |
Other | 54 | 54 |
Less: Valuation allowance | (52,392) | (30,406) |
Total deferred tax assets | 2,884 | 2,873 |
Deferred Tax Liabilities | ||
Prepaid Expenses | (308) | (335) |
Fixed assets and other | (298) | (85) |
Right-of-use asset | (2,278) | (2,453) |
Total deferred tax liabilities | (2,884) | (2,873) |
Deferred taxes, net | $ 0 | $ 0 |
Loss Per Common Share - Computa
Loss Per Common Share - Computation of Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Earnings Per Share [Abstract] | ||
Net loss | $ (64,102) | $ (24,668) |
Net loss | $ (64,102) | $ (24,668) |
Weighted-average basic common shares outstanding (in shares) | 88,617,332 | 87,203,588 |
Weighted-average diluted common shares outstanding (in shares) | 88,617,332 | 87,203,588 |
Loss per share - basic (in dollars per share) | $ (0.72) | $ (0.28) |
Loss per share - diluted (in dollars per share) | $ (0.72) | $ (0.28) |
Loss Per Common Share - Antidil
Loss Per Common Share - Antidilutive Securities (Details) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Options to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 9,944,773 | 7,227,296 |
Restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 303,250 | 0 |
Warrants to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 31,288,034 | 413,320 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands | Dec. 31, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | $ 10,496 | $ 48,818 |
Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 31,621 | 73,404 |
Common stock warrant liability | 15 | |
Total financial liabilities | 15 | |
Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 21,125 | 24,586 |
Common stock warrant liability | 0 | |
Total financial liabilities | 0 | |
Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 10,496 | 48,818 |
Common stock warrant liability | 0 | |
Total financial liabilities | 0 | |
Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 0 | 0 |
Common stock warrant liability | 15 | |
Total financial liabilities | 15 | |
Commercial paper | Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 5,999 | |
Debt securities, available-for-sale | 4,497 | 15,991 |
Commercial paper | Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Debt securities, available-for-sale | 0 | 0 |
Commercial paper | Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 5,999 | |
Debt securities, available-for-sale | 4,497 | 15,991 |
Commercial paper | Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 0 | |
Debt securities, available-for-sale | 0 | 0 |
Corporate notes/bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 29,296 | |
Corporate notes/bonds | Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 29,296 | |
Corporate notes/bonds | Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
Corporate notes/bonds | Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 29,296 | |
Corporate notes/bonds | Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
U.S. Treasuries | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 2,253 | |
U.S. Treasuries | Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 2,253 | |
U.S. Treasuries | Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
U.S. Treasuries | Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 2,253 | |
U.S. Treasuries | Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
U.S. Government agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 1,278 | |
U.S. Government agency securities | Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 1,278 | |
U.S. Government agency securities | Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
U.S. Government agency securities | Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 1,278 | |
U.S. Government agency securities | Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities, available-for-sale | 0 | |
Money market funds | Fair Value, Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 21,125 | 24,586 |
Money market funds | Fair Value, Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 21,125 | 24,586 |
Money market funds | Fair Value, Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 0 | 0 |
Money market funds | Fair Value, Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 0 | $ 0 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) - Common Stock $ in Thousands | Dec. 31, 2021USD ($)shares |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Warrant liability | $ | $ 0 |
Number of shares called by warrants (in shares) | shares | 0 |
Fair Value Measurements - Recon
Fair Value Measurements - Reconciliation of Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements Using Significant Unobservable Inputs (Level 3) - Common Stock - Warrant Liability - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||
Beginning balance | $ 15 | $ 414 |
Gain included in other income (expense), net | (15) | (399) |
Ending balance | $ 0 | $ 15 |
Defined Contribution Plan - Nar
Defined Contribution Plan - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Retirement Benefits [Abstract] | ||
Expense recognized on defined contribution savings plan | $ 402 | $ 257 |
Commitments and Contingencies -
Commitments and Contingencies - Narrative (Details) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2021USD ($) | Feb. 25, 2022plaintiff | Feb. 11, 2022plaintiff | |
Loss Contingencies [Line Items] | |||
Aggregate consideration paid to NU for agreement obligations | $ | $ 11,413 | ||
Subsequent Event | |||
Loss Contingencies [Line Items] | |||
Number of plaintiffs requesting appointment as lead plaintiff | 2 | 4 | |
Number of plaintiffs that withdrew request for appointment as lead plaintiff | 2 |
Related-Party Transactions - Na
Related-Party Transactions - Narrative (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Board of Directors | Consulting services | ||
Related Party Transaction [Line Items] | ||
Expenses from transactions with related party | $ 75 | $ 100 |
Subsequent Events - Narrative (
Subsequent Events - Narrative (Details) - USD ($) $ in Thousands | Mar. 15, 2022 | Jan. 21, 2022 | Jan. 04, 2022 | Dec. 10, 2021 | Jan. 21, 2022 | Dec. 31, 2021 | Mar. 24, 2022 | Dec. 31, 2020 |
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 9,944,773 | 7,227,296 | ||||||
Chief Financial Officer | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 600,000 | |||||||
Pre-Funded Warrants | ||||||||
Subsequent Event [Line Items] | ||||||||
Warrants exercised (in shares) | 7,569,454 | |||||||
Shares issued for exercise of warrants (in shares) | 7,569,454 | |||||||
Proceeds from warrant exercises | $ 8 | |||||||
MidCap Credit Agreement | Secured Debt | ||||||||
Subsequent Event [Line Items] | ||||||||
Repayments of debt | $ 10,000 | |||||||
Subsequent Event | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 6,996,741 | |||||||
Subsequent Event | Chief Executive Officer | Matthias Schroff | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 881,200 | |||||||
Subsequent Event | Chief Financial Officer | Elias Papadimas | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 375,417 | |||||||
Subsequent Event | Director | Jeffrey Cleland | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 115,079 | |||||||
Subsequent Event | Director | Elizabeth Garofalo | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 150,000 | |||||||
Subsequent Event | Director | Bali Muralidhar | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 115,079 | |||||||
Subsequent Event | Director | James Sulat | ||||||||
Subsequent Event [Line Items] | ||||||||
Options outstanding (in shares) | 93,386 | |||||||
Subsequent Event | Pre-Funded Warrants | ||||||||
Subsequent Event [Line Items] | ||||||||
Warrants exercised (in shares) | 6,500,000 | 7,500,000 | ||||||
Shares issued for exercise of warrants (in shares) | 14,000,000 | |||||||
Proceeds from warrant exercises | $ 14 | |||||||
Subsequent Event | MidCap Credit Agreement | ||||||||
Subsequent Event [Line Items] | ||||||||
Payment for debt extinguishment | $ 506 | |||||||
Subsequent Event | MidCap Credit Agreement | Secured Debt | ||||||||
Subsequent Event [Line Items] | ||||||||
Repayments of debt | $ 7,500 |